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Abstract: 
Nova-1 is a neuron-specific RNA binding protein, distributed both in the nucleus and in 
the cytoplasm of several populations of neurons. The work presented here confirms that 
Nova-1 binds a sequence of RNA found in an intron of the glycine receptor a2 subunit 
pre-mRNA. Evidence that Nova-1 acts as a regulator of alternative splicing in transfected 
cell lines is presented. Furthermore, a direct role of Nova-1 on splicing is demonstrated 
by establishing an in vitro assay for Nova-l's regulatory role in splicing. Potential 
functional partners of Nova are suggested by the demonstration of physical interactions 
between Nova-1 and molecules whose action in the splicing machinery is well described, 
such as Ul 70K, a protein component of UlsnRNP, and U2AF65. 
The sedimentation properties of Nova in neuronal cytoplasmic extracts are consistent 
with the engagement of Nova in heterogeneous structures, probably mRNPs, and with 
polysomes, suggesting a role for Nova in the regulation of cytoplasmic phenomena of 
RNA metabolism, such as mRNA localization and translation. These considerations 
prompted a gene expression screen aimed to identify differences in the pool of mRNAs 
associated with heavy polysomes in wild type and Nova-1-null mice. Several genes 
whose mRNAs have been found to undergo changes in abundance specifically in the 
polysome fraction in the absence of Nova have described functional roles in post-synaptic 
terminal structure and functions. Nova-1 was also found to be a phospho-protein, and its 
phosphorylation site is in an alternative cassette exon. 
C h a p t e r 1 
AN INTEGRATED VIEW OF GENE EXPRESSION 
The journey of RNA from transcription to translation into protein has traditionally 
been described as a series of discrete steps that happen in well-defined compartments of 
the cell. Upon the completion of transcription, the pre-mRNA, coated by hnRNPs, 
undergoes capping of the 5' end, splicing of the intronic sequences, cleavage and 
polyadenylation in the nucleus; the mature mRNA is then exported in the cytoplasm, 
where it is translated and eventually decays. This view of gene expression as a succession 
of discrete steps was suggested by the ability of in vitro assays to re-capitulate many of 
these events in isolation and by the non-overlapping localization in the nucleus of sites of 
transcription and sites containing splicing factors. While the view of a highly structurally 
and functionally compartmentalized cell and nucleus is still valid (Carmo-Fonseca, 2002; 
Spector, 2001), studies performed during the last decade are delineating a rather more 
integrated picture of the mechanisms of gene expression. Furthermore, it is becoming 
apparent that some RNA binding proteins are capable of playing more than one 
functional role in different compartments of the cell. The early post-transcriptional events 
of capping, splicing and poly-adenylation seem to all take place on RNAs which are still 
undergoing transcription or still engaged in the transcription machinery. I will briefly 
review some evidence of such integration, focusing on the splicing events. 
1) Transcription and pre-mRNA splicing: 
The idea that pre-mRNA splicing happens co-transcriptionally dates back to almost 
twenty years ago, when Fakan et al. suggested such relationship based on the localization 
of a subset of snRNPs in Perichromatin Fibrils, structures known to be enriched in newly 
synthesized pre-mRNAs (Fakan et al., 1984; Fakan et al., 1986). Furthermore, RNAs 
apparently undergoing splicing while still being transcribed were directly visualized by 
Beyer and Osheim by electron microscopy on chromatin spreads (Beyer and Osheim, 
1988; Osheim and Beyer, 1991). In the following years, a number of lines of evidence led 
to the current model, according to which pre-mRNAs are spliced co-transcriptionally, 
while Interchromatin Granule Clusters and Cajal bodies are highly dynamic storage 
and/or reassembly sites for SR proteins and snRNP, respectively, (Zhang et al., 1994), 
reviewed in Huang and Spector, 1997). 
The influence of the transcriptional promoter on the subsequent steps of RNA 
processing was first suggested by the observation that RNA polymerase II (RNAP II) 
genes expressed under the control of RNA polymerase III promoters were not processed 
properly (Sisodia et al., 1987). Subsequently, different RNAP II promoters, driving the 
transcription of the same a-globin/fibronectin reporter minigene, were shown to affect 
the splicing of an alternative exon (Cramer et al., 1999; Cramer et al., 1997). The ability 
of promoters to affect cassette exon utilization seems to correlate with their ability to 
influence RNAP II processivity, defined as the ability to elongate through sites where the 
polymerase is prone to pause or premature termination (Kadener et al., 2001; Kadener et 
al., 2002). Two not mutually exclusive models have been proposed to account for the 
observed effects of transcriptional enhancers, promoters and activators on alternative 
splicing. According to one model, promoters would have differential ability to recruit 
different sets of splicing factors, which would then be able to differentially splice nascent 
RNAs. The alternative model proposes that the effect of promoters on splicing is due to 
their ability to provoke the commitment of more or less processive RNAP II. In the case 
of one alternatively included cassette exon, low RNAP II processivity and internal pause 
would favor the presentation of the upstream, alternative 3'splice site to the splicing 
apparatus before the downstream constitutive 3' splice site has been synthesized, thus 
favoring the exon-including product (Caceres and Kornblihtt, 2002). The kinetic model 
has been directly verified in recent studies, in which the processivity of RNAP II was 
decreased pharmacologically or by inserting pause elements downstream of the 
alternative exon (Nogues et al., 2002; Roberts et al., 1998). 
The integration between RNA processing events described so far involve 
upstream events (like transcription) affecting downstream events (like splicing). A set of 
recent studies shows that RNA processing factors can feed back, in turn influencing 
transcription rate. In vitro studies show that TFIIH contains stochiometric amounts of Ul 
snRNA, and that depletion of U1 snRNA makes the TFIIH less efficient in "abortive 
initiation" and re-initiation assays (Kwek et al., 2002). Consistent with this finding, a 
promoter-proximal 5' splice site, recognized by Ul snRNA, stimulates the rate of TFIIH-
dependent re-initiation in vitro and the overall rate of transcription in vivo (Furger et al., 
2002; Kwek et al., 2002). Furthermore, the TAT-SF1 transcription factor was found to 
form a complex with U snRNPs, and to stimulate transcriptional elongation. The 
stimulation was more efficient when functional splice sites were present in the 
transcribed product (Fong and Zhou, 2001). These recent findings are beginning to 
provide a mechanistic explanation for the increased efficiency of transcription of 
transgenes with artificial introns near the 5' end, observed more than ten years ago 
(Brinster et al., 1988; Palmiter et al., 1991). 
2) Molecular Aspects of Transcription-RNA Processing integration: 
Interestingly, RNAP II itself has been identified as a component of the pre-mRNA 
splicing machinery. The largest subunit of RNA polymerase II is characterized by the 
presence of an unusual carboxy-terminal domain (CTD), rich in potential phospho-
acceptor aminoacid residues, comprised of a heptapeptide with the consensus Tyr-Ser-
Pro-Thr-Ser-Pro-Ser tandemly repeated fifty two times (in human). The 
hypophosphorylated form of the RNApol II (RNAP II A) is associated with the pre-
initiation complex, while the hyperphosphorylated form (RNAP II O) is associated with 
transcription elongation complexes that have cleared the promoter area (reviewed in 
(Howe, 2002) 
RNAP IIO was found to be specifically associated with functional splicing complexes, 
and a dramatic inhibition of pre-mRNA splicing (and 3'processing) was observed in cells 
in which the only active form of RNAP II had a CTD truncation (McCracken et al., 
1997b; Mortillaro et al., 1996). In a similar experimental setting, the recruitment of SC35 
and U2 snRNP to the transcription sites was shown to be impaired (Misteli and Spector, 
1999). These experiments suggest that the hyperphosphorylated CTD of RNAP II 
increases the local concentration of splicing factors, among which are SR proteins and 
SCAFs (SR-like CTD-associated factors), in proximity of the emerging transcript 
(Mortillaro et al., 1996; Misteli and Spector, 1999; (Yuryev et al., 1996). A direct role of 
R N A P II in promoting splicing independent of its function in transcription was also 
demonstrated. In an in vitro splicing assay employing pre-transcribed substrates, 
phosphorylated RNAP II was shown to promote the assembly of an early splicing 
complex, whereas the unphosphorylated isoform of RNAP II was shown to have the 
opposite effect (Hirose et al., 1999). 
The integration of transcription and splicing is only one aspect of a complex web of 
interactions that takes place in the nucleus during the early phases of RNA processing. 
The pre-RNA processing events of capping, splicing, and polyadenylation have been 
shown in recent studies to affect each other, and the hyperphosphorylated form of the 
CTD of RNAP II provides a platform for a number of biochemical interactions involved 
in the transcription and RNA processing events and their coupling (McCracken et al., 
1997a), reviewed in (Hirose and Manley, 2000; Hirose et al., 1999; Maniatis and Reed, 
2002; Proudfoot et al., 2002). Time course experiments have shown that RNA 
polymerases and RNA processing factors localize in large, discrete nuclear structures, the 
Cajal Bodies, upon their entry in the nucleus right after translation. Since no transcription 
or processing take place in the Cajal Bodies, these structures are currently interpreted as 
the assembly place of the large transcription-processing holoenzyme indicated as the 
transcriptosome (Gall, 2001; Gall et al., 1999). According to a recent model, from the 
Cajal Bodies, RNAP II and processing factors would then reach the transcription sites, 
where clusters of more than one polymerase would assemble into large "transcription 
factories", probably anchored to nucleo-skeletal structures (Cook, 1999; Iborra et al., 
1996; Maniatis and Reed, 2002). 
3) m R N A export is coupled with pre-mRNA splicing: 
The field of mRNA export has seen striking progress in the past few years. Nucleo-
cytoplasmic transport of protein and non-coding RNAs is largely mediated by transport 
receptors related (albeit often distantly) to Importing, moving their cargo (or complex of 
adapter and cargo) across the Nuclear Pore complex (NPC) along a gradient of RanGTP 
(Gorlich and Kutay, 1999). In only few instances has the export of mRNA been shown to 
fit this general paradigm. One such instance is the well characterized export of unspliced 
HIV genomic RNA. One intron in the unspliced HIV-1 RNAs contains the Rev Response 
Element (RRE), which is a binding site for several Rev adaptor molecules. The export of 
the RNA-Rev protein complex requires a nine aminoacid motif, characterized by four 
critically spaced Leucines, called Nuclear Export Signal (NES) (Malim et al., 1989). The 
NES motif has been found in several other proteins undergoing nucleo-cytoplasmic 
export, and has been shown to be required for the interaction with CRM1, an export 
receptor belonging to the importing family (Cullen, 2000; Fischer et al., 1995). Similarly, 
messages containing A rich elements (ARE) in their 3'UTR were shown to be exported 
through a CRM1-dependent pathway: the protein HuR binds the ARE of these mRNAs, 
and it interacts, in turn, with two NES-containing proteins, APRIL and pp32 (Brennan et 
al., 2000). Furthermore, a parallel HuR-transportin2-dependent pathway for the export of 
ARE-containing mRNAs was also discovered (Gallouzi and Steitz, 2001). 
Unlike these few examples, though, the export of the bulk mRNA from nucleus to 
cytoplasm seems to follow a different route, as it is largely not affected by treatment with 
Leptomycin B, a specific inhibitor of CRM1 (Fornerod et al., 1997; Wolff et al., 1997). 
In particular, recent studies have elucidated a strict coupling between export and pre-
mRNA splicing. Experiments performed in Xenopus oocytes have shown that RNA 
resulting from splicing of precursors containing introns injected in the nucleus were 
exported with much higher efficiency than RNAs not containing introns. Despite the fact 
that RNAs resulting from splicing and intronless RNAs were identical in sequence, they 
were shown to be complexed with a different set of proteins, presumably recruited by the 
splicing machinery (Luo and Reed, 1999). This finding opened the hunt for the 
characterization of the splicing-dependent protein complex. In a series of elegant in vitro 
studies, a protein complex (called EJC: Exon Junction Complex) was shown to form 
twenty nucleotides upstream from the exon-exon junction following splicing, and to 
remain on the mRNA in the cytoplasm (Kataoka et al., 2000; Le Hir et al., 2000a; Le Hir 
et al., 2000b). The identification of some of the components of the complex, and genetic 
studies performed in yeast, led to the contemporary model of mRNA export. The splicing 
factor UAP56, a DEAD helicase originally discovered as a U2AF65 co-factor, was 
shown to recruit the protein adaptor Aly to the mRNA during the splicing reaction 
(Fleckner et al., 1997; Luo et al., 2001; Strasser and Hurt, 2001; Zhang and Green, 2001; 
Zhou et al., 2000). Aly/REF (and the yeast ortholog Yra 1) is bound, in turn, by the 
export receptor TAP (and the yeast ortholog Mex67), a protein that associates with the 
nuclear pore (Bachi et al., 2000; Segref et al., 1997). Studies in yeast indicate that TAP 
(Mex67) and UAP56 (Sub2, in yeast) interact with the same region of Aly (Yral) 
(Strasser and Hurt, 2001). Therefore, according to the current model, the splicing 
machinery would recruit Aly to the mRNP through UAP56 during the splicing reaction. 
Aly could even be recruited co-transcriptionally, by interaction with the transcription 
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elongation factors of the T H O complex (Strasser et al., 2002). Subsequently, TAP 
displaces UAP56 from its interaction with Aly and leads the mRNP to the nuclear pore 
for export (reviewed in (Maniatis and Reed, 2002; Reed and Hurt, 2002). 
4) Possible alternative routes of mRNA export in Metazoa: 
The model based on the function of EJC, Aly and TAP, which emerged mostly from 
studies in yeast, may not entirely account for the complexity of RNA export in metazoan 
cells. In a recent study, RNAi was used in Drosophila cells to ablate various components 
of the EJC separately and in combination. Interestingly, while TAP and UAP56 were 
shown to be required for export of the bulk of mRNA, even the simultaneous ablation of 
Aly, RNPS1, Y14 and Srml60 that is, all the known components of the EJC did not 
result in complete abolition of mRNA export, although a quite substantial nuclear 
accumulation of poly(A)+ RNA was observed (Gatfield and Izaurralde, 2002). This result 
raises the possibility that other essential adaptor proteins link UAP56 and TAP in higher 
eukaryotes, or other export receptors or parallel pathways exist. Consistent with this 
hypothesis, a number of RNA binding proteins have been implicated in the export of 
specific sets of messages. The heterogeneous nuclear ribonucleoproteins (hnRNP), a 
large family of around 20 proteins, are thought to bind nascent RNA during transcription, 
and to remain associated with nuclear mRNAs after splicing is completed (Nakielny and 
Dreyfuss, 1999). Certain hnRNPs, like hnRNP Al and hnRNPK, have been shown to 
shuttle between nucleus and cytoplasm, while others, like hnRNPC, are found exclusively 
in the nucleus (Pinol-Roma and Dreyfuss, 1991; Pinol-Roma and Dreyfuss, 1992). The 
shuttling hnRNPs were the first group of proteins implicated in mRNA export for a 
variety of reasons. They bind m R N A in both compartments (Pinol-Roma and Dreyfuss, 
1992); their export is mediated by NES elements, which are not part of their RNA 
binding domain (Michael et al., 1995); excess of hnRNP Al, or of its M9 shuttling 
domain, specifically blocks export of dihydrofolate reductase (DHFR) mRNA (Gallouzi 
and Steitz, 2001; Izaurralde et al., 1997); an Al-like hnRNP is associated with 
translocating Balbiani ring transcripts from the transcription site to the cytoplasm, 
passing through the NPC (Daneholt, 1997); and yeast strains mutant in Npl3p, a shuttling 
hnRNP, show nuclear mRNA accumulation (Lee et al., 1996). Therefore, it seems 
probable that hnRNPs play a role in the export of some mRNAs, but the details of the 
mechanism of this action and the features of the messages that undergo such mode of 
transport are not defined. 
Another class of RNA binding proteins that may play a role in RNA export is the 
SR family of proteins. A subset of SR proteins have been shown to shuttle between the 
nucleus and the cytoplasm (Caceres et al., 1998). Moreover, SR proteins bind exclusively 
to exon sequences in pre-mRNA and remain bound to the exons after the mRNA is 
spliced (Graveley, 2000). Two shuttling SR proteins, SRp20 and 9G8 have been 
demonstrated to promote the nucleocytoplasmic export of intronless mRNA encoding 
histone H2A (Huang and Steitz, 2001). Furthermore, SRp20 and 9G8 can be UV-cross-
linked to polyadenylated RNA in the nucleus and the cytoplasm, suggesting that they 
could affect some as yet unidentified step of RNA metabolism after the export from the 
nucleus (Huang and Steitz, 2001). 
The coupling of splicing and export has been interpreted as an RNA proofreading 
mechanism. The mRNA, bearing protein coding information, represents a small 
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percentage of the total pre-mRNA transcript: the average size of an exon is 140 
nucleotides while the size of introns can be in the thousands and tens of thousands of 
nucleotides. The splicing apparatus marks the final products of processing with a distinct 
set of proteins: the removed introns coated with a subset of hnRNPs, are prevented from 
exiting the nucleus and targeted to degradation, while the mRNA, complexed with 
adaptor proteins, export receptors, EJC proteins, and also some hnRNPs, is targeted for 
export and translation (reviewed in (Reed and Magni, 2001). 
5) Nonsense mediated decay (NMD): 
Interestingly, Nonsense mediated decay (NMD), another level of control of the quality of 
the exported message, has been found to be strictly coupled to the EJC deposited in the 
course of the nuclear processing of RNA. NMD occurs when translation terminates more 
than 50-55 nucleotides upstream of the 3'-most exon-exon junction. The EJC, which lays 
20-24 nucleotides upstream of the exon-exon junction, recruits Upf3/3X, a predominantly 
nuclear protein that remains on the mRNP upon export to the cytoplasm, where it 
interacts with the predominantly perinuclear protein Upf2 (Kim et al., 2001; Lykke-
Andersen et al., 2000; Lykke-Andersen et al., 2001). It is thought that, in the absence of 
premature termination codons, the ribosomes would remove the EJC from the mRNA 
during the first round of translation. If a nonsense mutation occurs more than 50 
nucleotides upstream from the exon-exon junction (which is considered to be the distance 
between the decoding site and the leading edge of the ribosome), the ribosome 
disassembles and the EJC remains in place. Upf 2 and Upf3/3X are then able to recruit 
Upfl, a group 1 helicase, and the other components of the degradation pathway (Sun et 
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al., 1998). The notion of a first "pioneering" round of translation, during which 
ribosomes scan the message for the presence of premature stop codons, was suggested by 
a recent study in which NMD was shown to take place in messages associated with 
nuclear cap binding protein CBC80, but not in actively translated mRNAs associated 
with the eIF4E (Ishigaki et al., 2001). Nonetheless, some important aspects remain 
unexplained, like the cellular compartment in which NMD takes place in the cell. While 
the requirement for scanning of the messages by ribosomes had suggested that NMD is a 
cytoplasmic phenomenon, fractionation studies have shown that most of the messages 
containing premature stop codons undergo NMD in the nucleus or in a functionally 
defined nucleus-associated compartment, which is thought to identify the set of messages 
in the process of exiting the nucleus but not released yet in the cytoplasm (reviewed in 
(Hentze and Kulozik, 1999; Maquat and Carmichael, 2001; Schell et al., 2002). 
Nonsense-associated altered splicing (NAS) is a putative correction response that 
upregulates alternatively spliced transcripts that skip premature termination codons 
(Cartegni et al., 2002; Maquat, 2002). This phenomenon and recent evidence suggesting 
translation of proteins in the nucleus (Iborra et al., 2001) suggest that scanning of the 
coding sequence of the message could take place in the nucleus (Wilkinson and Shyu, 
2002). 
6) From the nucleus to the cytoplasm: role of nuclear RNA binding proteins in 
translation: 
In prokaryotes, which lack subcellular compartments, translation is directly coupled to 
transcription. In nucleated cells it is generally accepted that molecular tags, such as 
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components of the exon junction complex, are loaded on transcripts as a result of nuclear 
RNA processing events and that these ultimately affect cytoplasmic RNA metabolism. 
Nonetheless, in only a few instances has the same RNA binding protein been shown to 
affect regulation of the same RNA in the two intracellular compartments. While this 
apparent incongruence probably results from the fact that a genome-wide search for 
target sequences has been undertaken only for a handful of RNA binding proteins, it 
remains possible that RNA binding proteins associate with not completely overlapping 
sets of RNAs in the nucleus and in the cytoplasm. 
In lower organisms, some RNA binding proteins have been shown to regulate 
expression of a single RNA both in the nucleus and in the cytoplasm (Gebauer et al., 
1997). The RNA binding protein Sex Lethal (Sxl) in Drosophila offers one of the most 
striking examples of such a mode of regulation. In addition to its role in sex 
determination through regulation of alternative splicing (reviewed in the next section), 
Sxl regulates dosage compensation by inhibiting the expression of msl-2 at the post-
transcriptional level in the female fly. In the nucleus, the presence of Sxl inhibits the 
splicing of a small intron in the 5' UTR of msl-2 in female flies. The retention of the 
intron in the 5'UTR is not in itself sufficient to inhibit the expression of msl-2, but 
provides a binding site for Sxl in the mature msl-2 transcript. In the cytoplasm Sxl 
inhibits the translation of msl-2 by binding the unspliced intron in the 5'UTR and another 
site in the 3'UTR (Bashaw and Baker, 1997; Gebauer et al., 1998). In a similar way, the 
Saccharomyces cerevisiae ribosomal protein L32 regulates its own expression at the level 
of both splicing and translation (Dabeva and Warner, 1993). 
In vertebrates, there has been no description of an RNA binding protein that 
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regulates a single R N A in both the nucleus and the cytoplasm. Nonetheless, two R N A 
binding proteins structurally similar to Sxl, Polypyrimidine Tract Binding protein (PTB) 
and hnRNP A2 have been shown to play roles in both splicing and translation. PTB is a 
well-described splicing factor, and was found associated with many picornavirus IRES 
elements; depletion/reconstitution experiments demonstrated that PTB stimulates 
translation (Kaminski et al., 1995; Kaminski and Jackson, 1998; Niepmann, 1996). The 
mechanisms used by PTB to enhance IRES-dependent translation are presently unknown. 
Although a role for PTB in the translation of cellular mRNAs has only been demonstrated 
in two instances (Kim et al., 2000; Pickering et al., 2003), the presence of IRES and PTB-
binding sites in the 5' untranslated region of a variety of cellular mRNAs suggests that the 
observations made in viruses may mirror a more widespread mechanism of translational 
control (reviewed in (Valcarcel and Gebauer, 1997). Furthermore, VgRBP60, a Xenopus 
laevis homolog of PTB, has been suggested to be involved in the localization of Vgl in 
the vegetal cytoplasm of the oocyte (Cote et al., 1999). HnRNP A2 is 68% identical at the 
amino-acid level to hnRNP Al, a well characterized alternative splicing regulator, and 
has itself a described ability to modulate alternative splicing (Bilodeau et al., 2001; 
Mayeda et al., 1994). In the cytoplasm of oligodendrocytes hnRNP A2 has been shown to 
interact with the mRNA of Myelin Basic Protein (MBP) forming large mRNPs 
transported along the cytoskeleton to the myelin compartment (Carson et al., 2001). 
Interestingly, the A2 response motif, a short purine rich sequence in the 3' UTR of MBP 
mRNA, has been demonstrated to act as a cap-dependent translational enhancer, the first 
such regulatory features described in a mammalian RNA (Kwon et al., 1999). The 
Chironomus tentans homolog of the closely related hnRNP Al, which has been mostly 
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characterized as a splicing regulator, has been shown to follow the Balbiani ring (BR) 
RNA from the nucleus to the cytoplasm, where it remains bound to the mRNA engaged 
in actively translating giant polysomes (Visa et al., 1996). A further example of a nuclear 
and cytoplasmic RNA binding protein whose functional role has been characterized in 
both compartments is offered by the strictly related hnRNP K, El and E2. HnRNP K has 
recently been suggested to play a role in the regulation of alternative splicing of the (3-
tropomyosin pre-mRNA (Expert-Bezancon et al., 2002). HnRNP K binds an intronic 
pyrimidine-rich element thirty-seven nucleotides downstream of the 5' splice site of a 
regulated exon; the presence of the intronic enhancer correlates with increased 
recruitment of Ul snRNP (Expert-Bezancon et al., 2002). In the cytoplasm, hnRNP K, El 
and E2 are well-characterized regulators of translation and stability of specific messages: 
they inhibit the initiation of translation of the 15-Lipoxygenase mRNA by binding a 
pyrimidine-rich repeated sequence in the 3'UTR of the message, and affecting the 
assembly of the two ribosomal subunits (Ostareck et al., 2001; Ostareck et al., 1997). 
Furthermore, hnRNP Es (also called aCPs or PCBPs) are known to stabilize a-globin 
mRNA during erythroid differentiation by interacting with C-rich 3'UTR determinants 
(Makeyev and Liebhaber, 2002). Therefore, the ultimate outcome of the interaction of 
hnRNP E with the 3'UTR of the 15-lipoxygenase mRNA is reduced translation, while the 
interaction with the a-globin mRNA results in enhanced protein synthesis. 
A L T E R N A T I V E SPLICING A N D T R A N S L A T I O N A L C O N T R O L IN T H E 
N E R V O U S S Y S T E M 
15 
The astonishing complexity of the architecture of the neural system and the variety of 
its cell subtypes with unique connectivity patterns have suggested the need for this tissue 
to utilize mechanisms that expand proteome complexity. Alternative splicing and RNA 
editing are known to play important roles in expanding the repertoire of final protein 
products of individual genes, while two other mechanisms responsible for the generation 
of the diversity of immunoglobulin and T-cell receptors, genomic re-arrangement or 
somatic hypermutation, have not at present been described in the nervous system. 
Functional characteristics pose specific requirements on mechanisms of gene 
expression in the nervous system. The transmission of neuronal stimuli occurs in 
specialized synaptic structures that can be up to several hundred microns away from the 
neuronal cell body. Furthermore, studies by electrophysiology have shown that 
phenomena of synaptic plasticity can take place in dendritic terminations that have been 
severed from the cell bodies, indicating a remarkable functional autonomy of the synapse. 
In particular, a now substantial body of work has illustrated the role of translation of 
localized messages in the synapse in different aspects of synaptic plasticity. In the 
following section I will review some aspects of alternative splicing and translational 
regulation of gene expression in the nervous system. 
1) Specific aspects of translational control in neurons: 
Dendrites are extended and intricate structures, forming thousands of synapses 
that can lay hundreds of micrometers far from the cell body. Synapses are plastic 
structures, able to change their functional characteristics in response to activity. Since 
several experimental paradigms of synaptic plasticity require protein synthesis, the 
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distance from the cell body could pose a problem to the cell that has to provide the 
synapses with new proteins. The discovery that virtually all the components of the 
translational apparatus can be found in the post-synaptic specializations of dendrites 
suggested that translation of new proteins could actually happen locally, providing a 
mechanism for swift changes of concentration of proteins in response to stimulation 
(Gardiol et al., 1999; Steward and Levy, 1982). Furthermore, the local synthesis of 
proteins at the synapse circumvents the need of targeting proteins newly synthesized in 
the cell body to the activated synapse, offering a possible mechanistic explanation for the 
documented restriction of enduring functional modification to the stimulated synapse 
(reviewed in (Steward and Schuman, 2001). In the twenty years following the initial 
finding of ribosomes in the dendrites, several groups have pursued the identification of 
mRNA localized in the dendrites. There are currently about a dozen mRNAs that are 
universally recognized as localized in the dendrites, but it is commonly believed that 
many more have not been identified yet (Steward and Schuman, 2001). Notably, several 
identified mRNAs localized in dendrites encode for proteins for which a role in synaptic 
plasticity has been demonstrated: CaMKIIa mRNA, which encodes for the cc-subunit of 
CaMKII, a kinase required for the establishment of both Long Term Potentiation (LTP) 
and Long Term Depression (LTD), NRI, encoding a subunit of the TV-methyl-D-aspartate 
receptor (NMDAR), Arc, BDNF, and TrkB (Steward and Schuman, 2001). Dendritic 
translation has been described both as a consequence of synaptic plasticity and as a 
necessary condition for synaptic plasticity. Synaptoneurosomal preparations have been 
stimulated in various ways to show increase of translation of FMRP and CaMKII a-
subunit by pulse labeling techniques (Bagni et al., 2000; Leski and Steward, 1996; 
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Scheetz et al., 2000). Furthermore, stimulation with B D N F results in the increased 
dendritic translation of a reporter message containing the GFP coding sequence preceded 
and followed by the 5' and 3' untranslated regions of a CaMK II mRNA in intact 
neurons and in dendrites severed from cell bodies (Aakalu et al., 2001). Reciprocally, in 
hippocampal slices, synaptic potentiation induced by BDNF is blocked by inhibitors of 
protein synthesis, also in severed dendrites, demonstrating the requirement of local 
translation for synaptic potentiation (Kang and Schuman, 1996). LTD induced through 
metabotropic glutamate receptor stimulation has also been demonstrated to depend on 
protein synthesis in isolated dendrites (Huber et al., 2000) In a culture preparation of 
Aplysia sensory and motor neurons, a branch-specific form of long-term facilitation, 
induced by repeated application of serotonin, has been shown to be protein synthesis-
dependent (Casadio et al., 1999; Martin et al., 1997). More recently, the localization of a 
CaMK II mRNA in the dendrites was impaired by modifying the 3' UTR by homologous 
recombination in mice (Miller et al., 2002). The absence of localized synthesis of a 
CaMK II showed reduced late-phase long term potentiation, and various behavioral 
defects (Miller et al., 2002). 
2) Proposed mechanisms of translational regulation in dendrites: 
Two main modes of regulation of translation in dendrites have been described. 
Synaptic stimulation induces the transcription of immediate early genes, which are 
specifically transported to the stimulated synapse and translated. Alternatively, mRNAs 
are constitutively present at the synapse, and the stimulation activates their translation. 
The first mode of regulation has been best characterized for the gene Arc, which encodes 
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a cytoskeleton-associated synaptic protein that is required for the maintenance of LTP in 
the hippocampus (Guzowski et al., 2000). Patterned synaptic activation using a 
stimulation paradigm that is commonly used to induce LTP, both induced Arc 
transcription and caused the newly synthesized mRNA to localize selectively to activated 
synapses (Steward et al., 1998). An increase of Arc protein in the stimulated dendritic 
domains was also observed, suggesting that the events of mRNA localization and its 
translation are coupled in response to synaptic stimulation (Steward et al., 1998; Steward 
and Worley, 2001). 
In other instances, the mRNA seems to be constitutively localized in the post-synaptic 
areas, and synaptic stimulation activates its translation. Several not exclusive mechanisms 
have been invoked for the coupling of synaptic stimulation and activation of translation. 
The inhibition by rapamycin of long term facilitation in Aplysia neurons, and of LTP in 
hippocampal neurons, suggest a role of the protein kinase target of rapamycin (TOR) in 
the regulation of synaptic translation (Casadio et al., 1999; Tang et al., 2002). TOR 
promotes translation through two pathways: it stimulates initiation of translation by 
phosphorylating the eI4E binding protein (4EBP), which, in the hypophosphorylated 
state, sequesters the initiation factor 4E. Furthermore, TOR activates p70 S6 kinase, 
which, in turn, phosphorylates the ribosomal protein S6, and facilitates the translation of 
mRNAs containing a 5' terminal oligopyrimidine tract (5' TOP), a group of RNAs that 
encode several factors involved in translation (reviewed in (Raught et al., 2001). 
Besides general activation of cap-dependent translation through activation of TOR, 
other mechanisms have been proposed for activation of specific mRNAs in response to 
synaptic stimulation. NMDAR stimulation has been shown to rapidly increase a CaM II 
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synthesis, while reducing overall translation in synaptoneurosomes from rat superior 
colliculus (Scheetz et al., 2000). The increase of a CaM II synthesis is accompanied by 
phosphorylation of eukaryotic elongation factor 2 (eEF2), a modification known to 
reduce the elongation rate. A similar stimulation of a CaM II synthesis is obtained by 
treatment with cyclohexamide, a drug that inhibits the elongation step of translation. It 
has been speculated that, when the elongation step of translation becomes rate-limiting, 
the translation of messages that are abundant, but usually inefficiently initiated, like a 
CaM II, are up-regulated (Scheetz et al., 2000). 
Cytoplasmic polyadenylation has also been proposed as a possible mechanism for the 
regulation of dendritic translation. This mechanism was first characterized in Xenopus 
oocytes: a number of maternally transcribed mRNAs contain a very short poly(A) tail and 
are kept untranslated until fertilization. Upon fertilization, the inhibition of 
polyadenylation and translation exerted by the cytoplasmic polyadenylation element 
binding protein (CPEB) is removed by activation of the Aurora protein kinase, a longer 
poly(A) tail is synthesized, which is bound by Poly(A) Binding Protein (PABP), which, 
in turn, recruits eI4F complex, promoting initiation of translation (reviewed in (Mendez 
and Richter, 2001). It has been shown that the a CaM II mRNA contain two CPE in its 
3'UTR and that these two elements are functional in repressing translation when a CaM 
II is micro-injected in oocytes (Wu et al., 1998). Furthermore, other components of the 
cytoplasmic polyadenylation apparatus are present in dendrites of hippocampal neurons 
and increased length of the poly-A tail of a CaM II was observed in response to visual 
experience (Wu et al, 1998). These findings were further explored in cultivated neurons, 
where stimulation of NMDAR receptors was shown to induce translation of a reporter 
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under the control of a C a M II CPE (Huang et al., 2002; Wells et al., 2001). A recent 
study shows that CPEBP also facilitates the transport of a CaM II mRNA in the 
dendrites, presumably in a dormant state, since maskin, the protein involved in translation 
repression of CPE-containing messages, is also part of the mRNP complex. Neurons 
lacking CPEB or expressing a mutated form of the protein show slower and decreased 
transport of the substrate mRNAs (Huang et al., 2003). 
The local synthesis of proteins requires the translocation of the mRNAs encoding 
them from the cell body to the synapses, either in response to stimulation, as in the case 
of Arc, or constitutively, as in the case of a CaM KII (Ouyang et al., 1999). The 
trafficking of mRNA to sites of translation involves the recognition of cis-acting 
sequences, frequently in the 3'UTR, by trans-acting proteins. These messenger 
ribonudeoprotein (mRNP) complexes bind to cytoskeletal elements, which drive their 
transport and localization. The physical nature of the mRNPs is debated. The existence of 
extremely large RNA "granules" has been proposed based on studies in cultured primary 
neurons (Krichevsky and Kosik, 2001). These structures sediment faster than the largest 
polyribosomes on linear density gradients and seem to contain messenger RNAs, 
ribosomes and RNA binding proteins. Depolarization of neurons provokes redistribution 
of some mRNAs from the granules to the actively translating polysomes (Krichevsky and 
Kosik, 2001; Krichevsky and Kosik, 2002). Other studies have proposed that the mRNP 
structures devoted to transport and storage of mRNAs are rather heterogeneous in size, 
but smaller than the polyribosomes (Feng et al., 1997; Khandjian et al., 1996). 
It has been postulated that through the recognition of shared cis-acting sequences in 
discrete sub-populations of RNAs, RNA-binding proteins can post-transcriptionally 
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regulate the expression of functionally related genes (Keene and Tenenbaum, 2002). It is 
conceivable that, in the neurons, specific sets of RNA binding proteins may target 
mRNPs to specific synapses and confer translational regulation in response to 
stimulation. 
3) Alternative splicing as a mean to generate proteome complexity: 
The contemporary view of genome complexity is remarkably different than what 
was anticipated ten years ago, when numbers of genes higher than 105 were commonly 
estimated. With a number of genes probably not much higher than thirty thousand, only 
around twice the number of genes of the Drosophila genome (according to December 
2002 estimations (Waterston et al., 2002), the mammalian genome has to account for the 
startling complexity of higher vertebrates. One probably important source of complexity 
of the vertebrate proteome is the presence of vertebrate-specific protein domains and 
motifs (7% of the total), and the arrangement of pre-existing domains in a more variegate 
repertoire of architectures (Lander et al., 2001). The richer set of protein domains 
suggests a higher potential for regulation at the level of interactions among proteins and 
pathways. Other mechanisms often invoked to explain the complexity of vertebrates are 
pre-mRNA editing and post-translational protein modifications (Banks et al., 2000; 
Keeganetal., 2001). 
Alternative splicing offers an obvious mechanism through which an organism can 
expand the proteome from a limited number of genes, by combining exons in multiple 
different ways. While some general principles governing alternative splicing and 
examples of remarkably complex patterns of alternative usage of exons have been known 
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for more than a decade, only in the past two years has a systematic appreciation of the 
quantitative significance of this mode of gene expression begun to emerge. The 
completion of the human and murine genome drafts and the progress of the expressed 
sequence tag (EST) project and the RIKEN Mouse Gene Encyclopedia Project allow for 
the first time to compare cDNA sequences to the entire genome (Gregory et al., 2002; 
McPherson et al., 2001; Okazaki et al., 2002; Venter et al., 2001). Several groups 
undertook comparisons between ESTs derived from the same gene, followed by 
assessment of the candidate splice sites by alignment of the ESTs to the genomic 
sequence of the gene (reviewed in (Modrek and Lee, 2002). They estimated an alternative 
splicing frequency ranging between 35 and 59% of the human genes. These estimations 
were confirmed by a large international effort to compare 60,770 full-length cDNA 
sequences to the newly released draft of the mouse genome (Okazaki et al., 2002). This 
study estimated a 41% frequency of alternative splicing, in good agreement with the most 
recent EST-based studies (Modrek et al., 2001). These studies also agree on a high ratio 
(more than 70%) of alternative splicing events affecting the coding sequence (Modrek et 
al., 2001). While the quantitative impact of alternative splicing on gene expression 
appears indisputable, its role in expanding the proteome in vertebrates relative to other 
organisms is still debated. A survey of the frequency of alternative splicing across 
different organisms shows no appreciable difference between vertebrate and invertebrate 
(Brett et al., 2002). However, due to the incomplete coverage of the EST database in 
some of the organisms analyzed, the authors of this study were forced to compare a 
limited set of cDNAs, leaving out cDNAs with more complex patterns of alternative 
splicing. It is possible that once the comparison of all the cDNAs becomes possible, 
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differences across species may emerge (discussed in (Maniatis and Tasic, 2002). 
4) Alternative splicing and the Nervous System: 
A recent analysis of the public databases shows that 10-30% of human alternatively 
spliced genes show a tissue-specific pattern of exon utilization (Xu et al., 2002). The 
tissue with the largest total number of tissue-specific splice form was brain, which 
represented 18% of all the observed tissue-specific alternative splicing events (Xu et al., 
2002). This is consistent with results of previous studies that had shown that nervous and 
immune system account for the highest frequency of alternative splicing (Modrek et al., 
2001; Stamm et al., 2000). These studies provide the first quantitative support to the 
concept that the Central Nervous System (CNS) utilizes alternative splicing as a mean to 
increase the complexity of its proteome, and, therefore, its ability to give rise to many 
different cell subtypes and innumerable synaptic connections, an idea that has been quite 
popular for a number of years (Darnell, 1998; Grabowski, 1998). 
The concept that the CNS needs a very large repertoire of different molecules 
derives intuitively from the large number of neurons (estimated to be roughly 1010), the 
vast variety of neuronal subtypes and the high number of specific synaptic connections 
among them (up to 105 in a single Purkinje neuron). Sixty years ago, Roger Sperry's 
seminal experiments provided the first evidence that axon guidance and establishment of 
synaptic connections are governed by chemospecificity, or by specific sets of molecules 
guiding axons to their targets. It is currently widely believed that the diversity of neuron 
subtypes and the complexity of their synaptic connections reflect differential gene 
expression that confers each neuron's morphology, position, connectivity and 
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physiological characteristics. For example, motor neurons of the spinal cord have been 
shown to be grouped in multiple pools, each characterized by the expression of a unique 
combination of transcription factors and signaling molecules, with different muscle 
targets and afferent connections (reviewed in (Jessell, 2000). Another striking example of 
neuronal molecular diversity is the olfactory system, where each olfactory neuron 
expresses only one of over 1000 odorant receptor genes, and the receptor defines the 
neuron's connection in the brain (Mombaerts et al., 1996). 
Consistent with a suggested role of alternative splicing in expanding the ability of the 
CNS to establish specific intercellular contacts and communications, Modrek et al. show 
that 29% of the messages undergoing tissue-specific alternative splicing encode 
membrane-anchored receptors, integral membrane proteins and proteins involved in cell 
surface adhesion (Modrek et al., 2001). It is indeed among genes involved in adhesion 
and axonal guidance that the most complex patterns of alternative splicing have been 
described. Dscam, a Drosophila homologue of human Down Syndrome cell adhesion 
molecule expressed in the axon processes, can potentially give rise to as many as 38,016 
isoforms, by alternative splicing of four clusters of tandemly arranged exons (Schmucker 
et al., 2000). Nearly 3,000 neurexins, a group of neuronal cell surface receptors proposed 
to have a key role in synaptic formation, are predicted to arise by alternative splicing 
from 6 primary transcripts, deriving from three genes with two alternative transcription 
initiation sites each (Missler and Sudhof, 1998). It has been proposed that the diversity of 
neurexins might be a component of a code that specifies neural connectivity (Missler et 
al., 1998). Interestingly, the alternative splicing pattern of neurexin is much simpler in 
Drosophila than in vertebrate (Tabuchi and Sudhof, 2002), suggesting that the much 
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higher number of neurexin isoforms may have evolved to match the more complex 
architecture of the vertebrate neural system. The family of the a, p\ y protocadherins 
(Pcdh) is another source of neuronal protein diversity. The organization of the Pcdh 
genes is reminiscent of Immunoglobulin and T cell receptor loci, with clusters of 14 to 22 
tandemly arranged alternative exons encoding the variable extracellular domain, and 3 
constitutively spliced exons encoding the intracellular constant part. A separate promoter 
precedes each variable exon. Cis-splicing and, to a minor extent, trans-splicing, has been 
shown to take place between the variable and the constant exons, and the differential 
promoter choice is proposed to determine the usage of the 5'-most variable exon (Tasic et 
al., 2002; Wu and Maniatis, 2000; Wu et al., 2001). 
5) Mechanisms of Alternative Splicing: 
The fundamental step in alternative splicing, as in constitutive splicing, is 
discrimination of the part of the pre-mRNA that will be utilized in the message (exon), 
from the part that will be excised and eventually degraded in the nucleus (intron). The 
definition of exon-intron boundaries is dictated by the interaction of ds-elements and 
i*ran.y-acting factors. The information content of the primary sequence is rather limited: 
the splice sites consensus sequences are short and degenerate in metazoans. The splicing 
reaction occurs in the spliceosome, a complex molecular machinery constituted by the 
five small nuclear Ribonudeoprotein Particles (snRNP Ul, U2, U4, U5, U6), and more 
than 60 non-snRNP proteins (Will and Luhrmann, 2001). The early steps of splicing 
involve the recognition of the 5' splice site by Ul snRNP, the binding of SF1 to the 
branch point, and of U2AF65 and 35 to the polypyrimidine tract and the AG at the 3' 
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splice site, respectively. Subsequently, U 2 snRNP interacts with the branch point, and 
U4,U5,U6 enter the complex giving rise to the catalytically active spliceosome (reviewed 
in Burge, C.B., et al., 1998). Vertebrate exons are usually short (140 nucleotides on 
average) while introns can be tens of thousands of nucleotides long. The recognition of 
the splice sites is enhanced by interactions across the exon between splicing factors 
recognizing the 3' splice site and splicing factors bound to the 5' splice site, in a process 
called exon definition (Berget, 1995). A number of non-snRNP proteins take part in both 
the constitutive assembly of the spliceosome and the regulation of alternative splicing. 
Splicing regulators, most of which are RNA binding proteins, can modulate splicing by 
binding constitutive consensus sequences at the splice sites, branch point and 
polypirymidine tract, or specialized cis regulatory elements known as exonic enhancers 
and silencers (ESE and ESS) or intronic enhancers and silencers (ISE and ISS). 
Three not mutually exclusive mechanisms have been shown to be responsible for 
alternative splicing in different cell types or in cells in different physiological conditions. 
Transcription promoters can affect the pattern of splicing by recruiting splicing 
factors to the promoter area through interactions with transcriptional activators bound to 
transcription enhancers or with the Carboxy-Terminal-Domain (CTD) of the RNAP II, or 
by affecting the processivity of RNAP II (see the section on coupling of transcription and 
splicing). 
Varying the concentration of general splicing factors in in vitro splicing assays or by 
transfection in cell culture has been shown to affect the pattern of alternative splicing. 
ASF/SF2 and hnRNP Al have been shown to have competing effects on the splicing of a 
reporter minigene that could produce two splicing products differing in the usage of two 
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alternative 5' splice sites. Excess ASF/SF2 has been shown to promote the utilization of 
the more proximal 5' splice site. The addition of hnRNP Al competes the ASF/SF2 
effect, promoting the usage of the more distal 5' splice site (Caceres et al., 1994; Ge and 
Manley, 1990; Krainer et al., 1990; Mayeda and Krainer, 1992). HnRNP Al can promote 
the usage of the most distal 5' splice site by reducing the occupancy of both 5' splice 
sites by Ul snRNP, by cooperative binding that seems to be independent of the presence 
of high affinity binding sites (Eperon et al., 2000). Furthermore, a number of studies 
show that opposite actions of SR proteins and hnRNPs A and B regulate the inclusion of 
cassette exons. SR proteins usually activate the inclusion of cassette exons by binding to 
ESE sequences contained in the alternative exon and enhancing exon recognition, or by 
antagonizing the repressing actions of hnRNP A or B bound to nearby ESS elements 
(Zhu et al., 2001). HnRNP Al mediates silencing by recognizing initially a high-affinity 
binding site in the exon, which promotes the eventual interaction of hnRNP Al with the 
upstream region of the exon, and possibly with intronic sequences (Zhu et al., 2001). The 
opposing effects of SR proteins and hnRNPs have been shown to regulate many RNAs in 
a variety of systems (Bilodeau et al., 2001; Caceres and Kornblihtt, 2002; Caputi et al., 
1999; Cartegni and Krainer, 2002; Dirksen et al., 2000; Hou et al., 2002; Marchand et al., 
2002; Pollard et al., 2002; Smith et al., 2002; van der Houven van Oordt et al., 2000; Zhu 
et al., 2002). The abundance of both hnRNP Al and ASF/SF2 was found to vary widely 
across tissues, with variations in the molar ratio between the two proteins greater than 
100 times among certain tissues (Hanamura et al., 1998). It is conceivable that other 
general splicing factors belonging to the SR and hnRNPs families vary in a similar way 
across different tissues. Therefore, changes in the ratio between SR proteins and hnRNP 
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A/B may be crucial for the regulation of tissue-specific alternative splicing of a variety of 
messages. 
Another mechanism of alternative splicing regulation involves tissue- or 
developmental stage-specific factors. At present, there are only few examples of such 
factors, and they have been mostly discovered in systems amenable to genetic screening. 
This mode of regulation has been mostly investigated in the sex-determination cascade in 
Drosophila by a combination of genetic and biochemical means. The female-specific 
factor Sex-Lethal (Sxl) inhibits the utilization of male-specific 3'splice sites in 
Transformer (Tra) and on its own pre-mRNA. By competing with U2AF65 for the Tra 
polypyrimidine tract, Sxl promotes the utilization of a downstream female-specific 3' 
splice site in exon 2, and the skipping of a stop codon that produces an inactive Tra 
protein in male flies (Valcarcel et al., 1993). The female-specific Tra isoform, in turn, 
promotes the cooperative binding of two proteins containing RS domains, RBP1 and 
Tra2, to six ESEs in exon 4 of Doublesex (Dsx) pre-mRNA, which contains a stop codon 
(Hertel and Maniatis, 1998; Lynch and Maniatis, 1996). Exon 4 is included in the Dsx 
mRNA exclusively in female flies, resulting in an isoform of dsx that transcriptionally 
represses several male-specific genes. 
The Drosophila Half pint (HFP), which is expressed exclusively in the ovary in 
the adult fly, specifically regulates the alternative splicing pattern of ovarian tumor, 
eIF4E, and the constitutive splicing of gurken (Van Buskirk and Schupbach, 2002). The 
mammalian homolog of Half Pint, PUF 60, does not seem to have conserved the tissue-
and target-specificity of HFP, and appears to have a rather general splicing activation 
action (Maniatis and Tasic, 2002). 
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The Drosophila neural-specific R N A binding protein E L A V (embryonic lethal 
abnormal visual system) has been shown to be necessary and sufficient to produce the 
neural specific splicing pattern of neuroglian (Koushika et al., 1996), erect wing (ewg) 
and armadillo (Koushika et al., 2000). The effect on neuroglian splicing is dependent on 
the interaction of ELAV with uridine-rich intronic sequences (Lisbin et al., 2001). 
However, a neural-specific vertebrate member of the ELAV/Hu family, HuD, when 
expressed in Drosophila CNS under the control of an ELAV promoter, did not reproduce 
the ELAV effect on the neuroglian pre-mRNA splicing (Toba et al., 2002). 
Drosophila P-element somatic inhibitor (PSI), which is expressed exclusively in 
the somatic cells, prevents the production of a functional P-element transposase by 
inhibiting the excision of intron 3 (reviewed in Wang et al., 1997). 
N O V A , A NEURON-SPECIFIC R N A BINDING P R O T E I N 
1) Paraneoplastic Neuro-degenerations: 
The paraneoplastic neurologic degenerations (PNDs) are a group of very rare 
neuronal degenerations described in patients suffering a neoplasia outside the nervous 
system. It is a rather heterogeneous group of diseases, associated with various cancers 
and affecting different areas of the nervous system (reviewed in (Darnell and Posner, 
2003; Musunuru and Darnell, 2001). The immunologic nature of these diseases was first 
suggested by the discovery that the patients have high-titer autoantibodies reacting with 
antigens in both tumor and central nervous system (Posner, 1992). The sera of patients 
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were used to screen c D N A expression libraries, leading to the identification of 
autoantigens (reviewed in (Darnell, 1996). The targets of the autoantibodies were found 
to be proteins normally expressed exclusively in the neural system. It has been suggested 
that the expression of neural specific proteins in tumors growing outside the CNS elicits 
an immune response against those proteins, which are normally considered to be non-self 
because of their exclusive location in the "immuno-privileged" environment of the CNS 
(reviewed in (Darnell, 1996). 
Nonetheless, the observation that transfer of antibodies does not reproduce the 
disease in animals suggests that the presence of autoantibodies is not sufficient to cause 
the neurological degeneration (Darnell, 1996). Furthermore, most of the identified 
onconeural antigens are intracellular. A cell-mediated mechanism in paraneoplastic 
cerebellar degeneration has been unveiled based on the presence of expanded populations 
of onconeural antigen-specific cytotoxic T lymphocytes in patients (Albert et al., 1998). 
The cytotoxic activity of the T lymphocytes was shown to be much enhanced when the 
onconeural antigen, deriving from cells undergoing apoptosis, was cross-presented to the 
T-lymphocytes by dendritic cells (Albert et al., 1998). While the presence of a protein 
normally in immuno-privileged tissues in apoptotic cancer cells could lead to the 
observed tumor immunity, the mechanism responsible for the neurologic degeneration is 
still unexplained. It has been proposed that the auto-antibodies could enter neurons, and 
lead to neuronal death by interfering with the physiological functions of the onconeural 
antigens (Musunuru and Darnell, 2001). Even a limited number of apoptotic neurons 
could provide the antigenic material for cross-priming of cytotoxic lymphocytes, which 
would in turn trigger massive neural degeneration through a cell-mediated mechanism 
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(Musunuru and Darnell, 2001). 
The PND sera have proved a valuable reagent to identify a number of onconeural 
antigens. Based on the biological characteristics, these exquisitely neuron-specific 
proteins have been classified in four groups: neuromuscular junction proteins, vesicle-
associated nerve terminal proteins, neural signaling proteins, neuron-specific RNA-
binding proteins (Darnell, 1996). The two groups of RNA binding proteins identified as 
onconeural antigens, Hu and Nova, are of interest for their potential role in tissue-specific 
regulation of different steps of gene expression. 
Hu proteins are targets of autoantibodies in a set of PNDs called paraneoplastic 
Encephalomyelitis and Sensory Neuropathy (PEM/SN), a condition most commonly 
associated with small-cell lung cancer (SCLC), and some types of prostate cancer (Ball 
and King, 1997; Dalmau et al., 1992a; Dalmau et al., 1992b; Manley et al., 1995). There 
are four known Hu genes in mammals, termed HuA (or R) through D. While Hu B, C and 
D are neural specific and autoantibody targets in PND, HuA is ubiquitous. Hu proteins 
have been reported to be involved in mRNA export (Gallouzi and Steitz, 2001), 
stabilization of mRNAs containing AU-rich elements (ARE) in their 3'UTR (Fan and 
Steitz, 1998) and translational control (Antic et al., 1999). Interestingly, Hu exerts 
opposite effects on translation depending on the location of its binding site in the 
messages. Hu enhances translation of transcripts that interact with the protein in their 
3'UTR (Antic et al., 1999), but exerts an inhibitory effect on the translation of p27, by 
binding in the 5'UTR in a region of the transcript that functions as an internal ribosome 
entry site (Kullmann et al., 2002). Overexpression of Hu in P19 and P12 cells and ectopic 
expression in mouse embryos promotes a neural phenotype (Akamatsu et al., 1999; Antic 
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et al., 1999; Gao and Keene, 1996). In mouse embryonic cortex a hierarchy of different 
Hu messengers in neurons at different stages of migration was described (Okano and 
Darnell, 1997). 
2) POM A and the discovery of Nova: 
The Paraneoplastic-opsoclonus-myoclonus-ataxia (POMA) is a neural 
degeneration characterized by deficit of inhibitory control of the eye, limbs and trunk 
movements (Anderson et al., 1988; Budde-Steffen et al., 1988). It is a rather rare 
complication of breast and gynecological tumors and small cell lung cancers. In western 
blot analysis, sera from patients affected by POMA recognize two sets of four to five 
bands in neural extracts, migrating slightly above 50 kDa and around 70 kDa 
(Buckanovich et al., 1993). By screening expression libraries with POMA patient sera, 
two genes were cloned, termed Nova-1 and Nova-2 (Buckanovich et al., 1993; Yang et 
al., 1998). Nova-1 mRNA is expressed in neurons, mostly in the motor neurons of the 
ventral horns of the spinal cord, in the motor neurons of the hindbrain and in ventral 
midbrain (Buckanovich et al., 1993). Nova-2 mRNA is also exclusively neuronal, and its 
distribution in the CNS is roughly complementary to that of Nova-1. Nova-2 is most 
highly expressed in the cortex, olfactory bulb, thalamus, dorsal midbrain and inferior 
olive, with weaker levels of expression observed in the hindbrain and spinal cord (Yang 
et al., 1998). Both Nova proteins are most abundant in the nucleus, but they are also 
present in the cytoplasm and in the dendrites (Triller, A and Darnell, R.B., unpublished 
observations). 
3) Nova is a sequence specific RNA binding protein: 
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Nova-1 and Nova-2 contain three repeats of the K H domain (hnRNPK Homology 
domain), the second most common RNA binding motif, originally discovered in the 
hnRNPK protein (Siomi et al., 1993). Since the characterization of the original KH motif, 
a superfamily of more than 100 KH proteins have been identified in eukaryotes, 
eubacteria and archea (Lewis et al., 1999). KH motifs span about seventy residues, with a 
characteristic a/p fold consisting of a three-stranded, antiparallel (3-sheet backed by three 
a-helices, a Gly-X-X-Gly loop invariant among all the members of the superfamily, and 
a variable loop (Lewis et al., 1999). KH-containing proteins play a functional role in 
splicing, as PSI in Drosophila, MER-1 in yeast, SF1 and KSRP in mammals, and in 
translation, as hnRNPK, El and E2, and FMRP (Berglund et al., 1998; Brown et al., 
2001; Labourier et al., 2002; Min et al., 1997; Ostareck-Lederer et al., 1998; Spingola 
and Ares, 2000) . Each Nova protein contains three KH motifs, the first two in the N-
terminal half of the protein being separated by a short connecting region, with the third 
close to the C-terminus. A similar arrangement is observed in other KH domain-
containing proteins, like hnRNPK, hnRNPEl and E2. Nova-1 and Nova-2 are very 
similar in their amino acid sequence: Nova-2 is 75% identical to Nova-1. The highest 
level of sequence identity is observed in the KH motifs (87-93% amino acid identity). 
Extensive in vitro Selection-Amplification studies have been performed to 
identify specific RNA sequences that Nova binds with high affinity (Buckanovich and 
Darnell, 1997; Jensen et al., 2000b; Yang et al., 1998). Selection-Amplification 
performed with the entire Nova protein resulted in identification of a [UCAU(N)0_2]3 
motif, in the context of a stem-loop structure (Buckanovich and Darnell, 1997). The same 
study showed that the third KH domain was necessary and sufficient to bind the target 
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sequence. Additional R N A selection experiments performed with isolated KH3 domain 
resulted in the selection of a single UCAY motif in the context of a stem-loop structure, 
confirming the major role exerted by KH3 in the determination of the target sequences of 
the entire molecule (Jensen et al., 2000b). 
This target RNA was co-crystalized with the isolated KH3 domain and the 
structure was solved at 2.4 A resolution (Lewis et al., 2000). The single-stranded RNA 
sequence is pinioned between the invariant and the variant loops, and it stacks on a 
hydrophobic surface made of aliphatic chains of amino acids belonging to a helices and 
|3 strands. The central bases of the consensus sequence, C and A are specifically 
recognized thanks to the spatial arrangement of several polar and charged residues 
surrounding the hydrophobic surface, which mimic Watson-Crick-like C-G, A-U contact 
(Lewis et al., 2000). The bordering residues on the two sides of the CA core of the 
consensus sequence are also tightly specified, although less stringently, such that only a 
pyrimidine can fit. Furthermore, the crystallized RNA/KH3 complexes arrange 
themselves in dimers by interactions through their third a helix. This mode of 
dimerization, which has been confirmed in solution by Nuclear Magnetic Resonance 
(Ramos et al., 2002), would give the KH3 dimers the ability to bind two UCAY motifs, in 
agreement with the target consensus sequences selected by the entire protein, and with 
the few validated in vivo target sequences (see in the next sections), which all contain 
multiple repeats of the UCAY motif. The role of the first and second KH domains is not 
clear at present; while differences in critical amino acids make it improbable that they 
recognize the UCAY motif, they could recognize other RNA sequences, further 
specifying the in vivo targets, or participate in inter or intra-molecular dimer formation, 
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or engage in interactions with other proteins (Lewis et al., 2000; Ramos et al., 2002). 
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C h a p t e r 2 
MATERIALS AND METHODS: 
DNA preparation and restriction digest analysis 
Unless otherwise stated, all plasmid DNA was prepared using Spin mini-prep kits 
(Qiagen) and analyzed by restriction digestion using enzymes, buffers and protocols 
supplied by New England Biolabs. DNA was separated by electrophoresis in standard lx 
TBE/1-1.5% agarose gels and photographed under UV light. Plasmid DNA for 
transfections into cell lines was prepared by a modified cesium chloride method 
(Molecular Cloning, by Sambrook, Fritch and Maniatis, Cold Spring Harbor Laboratory 
Press, 1989), and dialyzed against lxTBE. 
Plasmid Constructs: 
The GlyRa2 minigene (cloned in pCDNA3, Invitrogen) corresponds to the following 
GlyRagr2 E2 mouse genomic sequences: bases 81-276 (GenBank accession number 
X75842), 63-583 (GenBank accession number X75843), and 10-300 (GenBank 
accession number 75844). The mutated GlyRa2 minigene, in which the Nova-1 binding 
site 5'-UCAUCAUCAUUUUCAUUUUGUUU-3' was mutated to 5'-UAA 
UAAUAAUUUUAAUUAAGGUU-3'. was generated by PCR. A cDNA encoding T7-
tagged Nova-1 was cloned into pcXHook (Invitrogen) and into pCI-neo (Promega). 
The |3-globin minigene was generated by PCR using primers glo-KpnF and glo-
Rc using plasmid sp64-H|3A6 (a kind gift from A. Krainer) as a template, and was cloned 
into pCDNA3 (Invitrogen). Exon 2 was shortened by PCR. Heterologous minigene 
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constructs were generated by PCR. 
Mutations of both minigene and Nova-1 expression constructs were made with the 
QuikChange Site-directed Mutagenesis Kit (Stratagene) and specifically designed 
primers (Operon). 
All DNA constructs generated by PCR were sequenced in their entirety. 
Cell transfection 
N2A and 293T cells were grown to 60% confluence in 6-well plates or chamber slides in 
10% FBS/DMEM with penicillin/streptomycin. For in vivo splicing assays, 2.25 jag of 
total DNA, comprised of 0.25 ug of the appropriate minigene, and variable amounts of 
pNova-1 and empty pclneo vector, were incubated with 95 ul of DMEM and 5 ul of 
Fugene6 (Roche) for 15 min at room temperature. The mixture was then added to the 
cells in a total volume of 2 ml 10% FBS-DMEM. After 40 hrs the cells were washed with 
lxPBS, collected by scraping and halved for RNA extraction and protein extraction. 
Transfection in chamber slides was performed by adding a mix of 0.25 ug of plasmid, 48 
ul of DMEM and 2 ul of Fugene6 to cells in a total volume of 1 ml 10% FBS-DMEM. 
293T cells (ATCC) are a primary human embryonic kidney cell line transformed with the 
SV40 T antigen. N2A cells (ATCC) are a mouse neuroblastoma cell line. 
RNA preparation 
Total RNA was extracted from mouse tissues using a modified guanidine-acid phenol 
protocol (Chomczynski et al., 1997). RNA from tissue culture cells was purified using the 
RNeasy Mini kit system (Qiagen), including on the column DNase 1 digestion. 
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RT-PCR 
Purified RNA was reverse transcribed using random hexamers and Superscript II reverse 
transcriptase (Invitrogen). cDNA products were amplified using PfuTurbo (Stratagene) 
with 40 pmol each primer, and 0.5 pmol of one y-32P-ATP-labeled primer. PCR products 
were separated by denaturing PAGE (6% acrylamide/7 M urea) and confirmed by 
sequencing. Quantification was performed using a Molecular Dynamics Storm 
Phosphorimager and ImageQuant software. PCR was linear with respect to input cDNA 
and cycle number (data not shown). 
Western blot analysis 
Tissue culture cells were lysed in PXL lysis buffer (lxPBS, 0.1% SDS, 0.5% DOC, 0.5% 
NP-40). Proteins were separated by 10% SDS-PAGE and transferred to PVDF 
membranes (Millipore). Equal loading of total protein was determined by Bradford 
assay. Membranes were blocked for one hour at room temperature in 5% non-fat milk in 
R buffer (0.15 M NaCl, 10 mM Tris-Cl, 1 mM EDTA, 0.1% Triton X-100), incubated 
with HRP-conjugated anti-T7 tag monoclonal antibody (Novagen) in 5% milk in R buffer 
at 4°C overnight and washed four times with alternating high salt (1 M NaCl, 20 mM 
Tris-Cl, 0.1% Triton X-100) and high detergent (0.15 M NaCl, 5 mM EDTA, 50 mM 
Tris-Cl, 1% Triton X-100, 0.05% SDS) buffers. After a final rinse with R buffer, signal 
was detected by chemiluminescence (NEN). The membranes were wrapped (Saran 
Wrap) and exposed on Biomax MR film (Kodak). 
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Nitrocellulose Filter Binding Assays 
Labeled RNA (100-200 nmol preheated to 75°C and bench-cooled 5 min) was incubated 
with the indicated concentrations of protein. Protein-RNA mixes were incubated in a total 
volume of 50 pL SBB (200 mM KOAc, 10 mM TrisOAc [pH 7.7], and 5 mM MgOAc), 
SBB 500 (500 mM KOAc, 10 mM TrisOAc [pH 7.7], and 5 mM MgOAc) or SBBhep 
(SBB + 1 mg/ml heparin) for 10 min at room temperature. Binding solutions were passed 
through MF-membrane filters (0.45 HA, Millipore) and washed with 5 ml SBB (or 
SBB500). Data were plotted as percentage of total RNA bound versus log of the protein 
concentration, and Kds were determined with Kaleidograph software (Synergy Software). 
GABA was transcribed using T7 RNA polymerase and gel-purified PCR templates 
generated using primers T7-GABA-9CF and xR' (wildtype, 159nt RNA) or i9AtoCR2 
(mutant, 156nt RNA) and GABAARy2 minigenes as PCR templates. Glo RNA was 
transcribed using T7 RNA polymerase directly from minigene glo2A digested with Bbsl, 
to yield a 175ntRNA. 
PCR Primers: 
The primers used were 
E2F: 5'-AGCTTTCTGCAAAGACCATGAC-3'; 
E4R: 5'-GAAGATCTCCAAATCCAAGGAATCATCTGGG-3'; 
agr2GlyRE3A: 5'-CATGGTGGTTTCTGTGACTGATC-3'; 
agr2GlyRE3B:5'-CATTGTAGTTTCTGCTATTGACCCAAAG-3'; 
agr2GlyRE4: 5'-TCCAAATCCAAGGAATCATCTGGG-3'; 
actinF:5'-GTGGGCCGCTCTAGGCACCA-3' 
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actinR: 5'-CCCCCCTGAACCCTAAGGCCAACCG-3'; 
mGluRlF:5'-CCTGGGGTGCATGTTTACTCC-3'; 
mGluRlR:5'-AGGCCGTCTCGTTGGTCTTCA-3'; 
ICH-1F: 5'-GTCTCATCTTCATCAACTCC-3'; 
ICH-lR:5'-ATGCTAACTGTCCAAGTCTA-3'; 
ClaBF: 5'-ACCGAACAGGAGTGGCGGGAG-3'; 
ClaBR: 5'-GGGGTCTCCTCCTTGGATTCT-3'; 
ggr2GABAF: 5'-GTATGGCACCCTGCATTATTTTGTC-3'; 
ggr2GABAR: 5'-TTGAATGGTTGCTGATCTGGGACG-3'; 
ChATF: 5'-ATGCCTATCCTGGAAAAGGTCCC-3'; 
ChATR:5'-AGTGCTCCGAGCAAAGATCACAG-3'; 
SrcF: 5'-CCAAGCTCTTCGGAGGCTTCAACTC-3'; 
SrcR: 5'-CACATAGTTGCTGGGGATGTAACCG-3'; 
AgrinF: 5'-GGGATAGTTGAGAAGTCAGTGGGGG-3'; 
agrin R: 5'-CGAAGCCAGCGGTTGGTGTTG-3'. 
T7-GABA-9CF: 5'- GAAATTAATACGACTCACTATAGGGAGCAGCTGCA 
CTGCTTAAGCGC-3' 
xR': 5'- TTTTGCTAGCCACAATGTCATCAATGAGATGATG-3' 
i9C-A R2: 5'- GTACTTCCACAATGTCATCAATTAGATTATTAATCTGAAAA 
TTAGTATTCAG AAA ATTGCTT-3' 
RT-PCR 
Purified RNA (Chomcynski and Sacchi, 1987 ) was reverse transcribed using random 
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hexamers, and c D N A products were amplified using PfuTurbo (Stratagene) with 40 pmol 
of each primer and 0.5 pmol of one ggr-32P-ATP-labeled primer. PCR products were 
confirmed by sequencing. PCR was linear with respect to input cDNA and cycle number 
(data not shown). 
In vitro Transcription and UV Cross-Linking 
RNAs for crosslinking were generated by PCR using the wild-type or mutant GlyRagr2 
minigene, followed by in vitro transcription. The primers used were T7primerl (sense) 
(5'-AGTAATACGACTCACTATAGGGATCATGCAGTTCTGGTTTAAT) and primer2 
(antisense) (5'-AGCTCCATCAACATCTGTGG), which amplified a 90 nt fragment 
surrounding the Nova-1 binding site. Gel-purified PCR products were used as templates 
for in vitro transcription. Thirty microliters of total cell extracts from mouse brainstem 
(50 /d///g) were irradiated with UV light for 15 min. The samples were treated with 80 U 
of RNAse A (Worthington) for 30 min at 37°C. UV cross-linking reactions were 
immunoprecipitated with a 5 y\ polyclonal rabbit anti-Nova-1 antisera in a total volume 
of 100 p\ of lysis buffer. The immune complexes were precipitated with protein 
A-Sepharose beads (Sigma), run on 10% SDS-PAGE gels, transferred to nitrocellulose, 
and exposed to film. 
Purification of Nova-1 fusion protein: 
Full length Nova-1 was cloned into pET21a (Novagen) and transformed into BL21 
competent cells, followed by standard IPTG-induction and purification by nickel-
chelation chromatography. The fractions containing recombinant Nova were further 
purified by affinity chromatography using an anti-T7 monoclonal antibody covalently 
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coupled to cross-linked agarose beads (Novagen). The bound protein was eluted with 0.1 
M citric acid, pH 2.2 directly in tubes containing 2 M Tris Base. Fractions containing 
protein were pooled and affinity purified with a poly(G) resin (Sigma) and eluted in 0.25, 
0.5 and 1 M NaCl. The fractions were pooled, dyalized against buffer D and concentrated 
in Slyde-A-Lyzer concentrating kit (Pierce). Nova fusion protein preparation were 
assessed for purity by electrophoresis on 5-20% polyacrylamide-SDS gels and Coomasie 
blue (BioRad) staining. 
In vitro splicing assay: 
Substrates GABA/Globin A, B and mutant were transcribed in the presence of o>32P-
UTP. Transcription conditions were as follows: 40 mM Tris-HCl (pH 7.9), 6 mM MgCl2, 
2 mM spermidine 0.5 mM ATP, CTP, GTP, 0.05 mM UTP, 1.65 pM ct-32P-UTP (ratio 
cold UTP/labeled UTP= 30.3), 0.2 mM m7dG(5')ppp(5')G, 1 mM DTT, 3 pg template 
DNA, 50U T7 RNA polymerase. The transcription mix was incubated 2 hrs at 37°C. 
After treatment with Dnase I (final concentration 30U/ml) 20 min at 37°C, the product 
was gel-purified using a 6% polyacrylamide 7M Urea gel. In vitro splicing assays were 
performed as described in Mayeda and Krainer, 1999. Briefly, the reaction was carried 
out in 25 \i\ total volume, with approximately 20 fmol of 32P-labelled, 7CH3-GpppG-
capped substrate, in the presence of 0.5 mM ATP, 2 mM creatine phosphate, 3.2 mM 
MgCl2, 2.6% (w/v) polyvinyl alcohol (PVA). The reaction contained 7.5 \x\ of HeLa 
nuclear extract in buffer D (20 mM Hepes-KOH, pH 8.0, 0.2 mM EDTA, 20% (v/v) 
glycerol, 100 mM KC1, 1 mM DTT, 0.5 mM PMSF), to which 1 to 3 pmol of NOVA-1 
recombinant protein in buffer D were added. Following incubation for 4 hrs at 30°C, the 
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R N A was extracted with Tryzol LS (Invitrogen), precipitated and analyzed on a 6% 
Acrylamide-Bisacrylamide (19:1), 7M Urea, IX TBE gel. The gel was dried and 
exposed. The intensity of the bands on the gel was quantified using a phospho imager. 
Debranching Assay: 
Bands were cut out of polyacrylamide dried gel, crushed in extraction buffer (0.5 M 
NH.Ac, 10 mM MgAc2, 1 mM EDTA, 0.1% SDS), eluted at 4°C for 6 to 12 hrs, and the 
gel debris eliminated by filtering the slurry through a glass pre-filter. The recovered RNA 
was precipitated. The de-branching assay was performed essentially as described in 
(Ruskin and Green, 1990). Briefly, the RNA was incubated in the presence of 15 uJ. of 
HeLa cytoplasmic S100 extract, 8 mM EDTA, in a final volume of 25u.l for 45 minutes at 
30°C. At the end of the incubation, RNA was phenol-chloroform extracted, precipitated 
and analyzed on a denaturing gel. 
Primer extension: 
RNA template was purified from denaturing gels as described above for the de-branching 
reaction. DNA primer antisense to the 3'splice site and polypyrimidine tract of the second 
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intron of GABA/globin splicing substrate was labeled with P-[y-ATP] and T4 
polynucleotide kinase, and gel purified. Around 25 Kcpm labeled oligo-primer was added 
to around 5 fmol of eluted RNA in IX annealing buffer (AB) 50 mM Tris pH 8.3, 60 mM 
NaCl, lOmM DTT in 6uJ total reaction volume and annealed by heating to 90°C for 3 
min and letting slowly reach 45°C. Primer extension was performed using Superscript II 
reverse transcriptase (Invitrogen) according to the manufacturer's protocol. 
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Immunoprecipitation from splicing reactions: 
Immunoprecipitation from in vitro splicing reactions was performed essentially as 
described (Blencowe et al., 1994). In vitro splicing reactions containing GABA/globin B 
substrate, GABA/globin B substrate in presence of 0.06 u.M recombinant Nova-1, 
GABA/globin mutant substrate in presence of 0.06 uM recombinant Nova-1 were scaled 
up seven times. Rabbit serum anti-mouse Fc was pre-adsorbed to protein A immobilized 
on Sepharose beads (Sigma). After three washes in IP100 (50 mM Tris 7.45, 100 mM 
NaCl, 2 mM MgCl2, 0.5 mM DTT, 0,05% (v/v) NP40), equimolar amounts of 
monoclonal antibodies against Sm domain (Y12; Neomarkers), T7 tag (Novagen) and 
purified mouse IgG (Pierce) were adsorbed to the protein A beads for 2 hrs at 4°C and 
washed four times in IP 100. At the end of the four hrs incubation, the splicing reactions 
were divided in four aliquots. Three aliquots from each reaction were used for 
immunoprecipitation with each of the indicated antibodies, and RNA from the remaining 
fraction was directly extracted as the input control. The aliquots used for 
immunoprecipitation were twice the size of the one from which RNA was directly 
extracted. After 1.5 hrs incubation at 4°C, the supernatant was removed and the pellet 
was washed three times in 1 ml IP100. The RNA was extracted from the 
immunoprecipitated pellets with Tryzol, and analyzed on denaturing PAGE. 
Yeast two hybrid assay: 
Full-length Nova-1 cDNA was cloned into the LexA vector pBTM116, and transformed 
into LD40 yeast strain. LD40 yeast are leu-/trp- and contain the lacZ and His-t- genes 
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under the control of LexA promoters. The bait constructs (a kind gift of David Elliot, 
MRC, Edinburgh, UK) were cloned in PAS vectors (Clontech). Transformations and tests 
for protein-protein interactions (growth in tip-, leu-, his- medium and production of (3-
Galactosidase) were performed according to standard protocols (Sambrook et al. 2001). 
GST pull-down assay in transfected cells: 
In vivo GST pull-down assays were performed by co-transfecting N2a cells in 10 cm 
diameter plates with constructs encoding the indicated proteins fused to GST subcloned 
in the PEBG eukaryotic expression vector (a gift of Dr. T Shishido), and vectors 
encoding T7-Nova. Cells were harvested 2 days later, lysed in LB50: 20 mM Tris 7.5, 50 
mM NaCl, 5 mM EDTA, 1% NP40, 1 complete tablet (Roche). Cells were sonicated, 
debrees removed by centrifugation (14.000 X g, 5 min), and glutathione-sepharose 4B 
(Pharmacia) beads were added. After overnight incubation, the beads were washed five 
times with LB50. During the third washing step they were incubated in 23 u.g/ml 
RNAseA for 20 min at 37°C. Proteins recovered in the pellet were analyzed by SDS 
PAGE and western blot. 
Sucrose Gradient centrifugation and Polysome Fractionation: 
Analysis of polysomes from cell lines on sucrose gradient was performed using standard 
protocols (Ruan et al., 1997). For each density gradient analysis of neural polysomes, 
four spinal cords and hindbrains were dissected. Hypotonic Low Salt Buffer (20 mM Tris 
7.4, 10 mM KC1, 5 mM MgCl2, 0.5 mM DTT, 1 complete mini EDTA free protease 
inhibitor cocktail (Roche) for 10 ml of buffer, 100 ug/ml Cycloheximide (CH), Rnasin 20 
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U/ml) was added to the dissected tissue in a proportion of roughly 0.25 ml of buffer for 
each 0.1 mg of tissue. The tissue was then homogenized in a motor-driven Teflon-Glass 
(900 rpm, 10 strokes), and nuclei were removed with a low speed centrifugation step 
(2,000 X g, 10 min), and the supernatant (SI) was collected. A volume of detergent 
solution (1.2% NP-40, 0.5 mM DTT, 100 [xg/ml CH, 1 complete mini EDTA free 
protease inhibitors cocktail (Roche), Rnasin 20U/ml) equal to 25% of the SI volume, and 
a volume equal to 10% of the sum of SI and detergent buffer of High Salt Buffer (20mM 
Tris 7.4, 1.5M KC1, 3mM MgCl2, 0.5mM DTT, 1 complete mini EDTA free, lOOug/ml 
CH, Rnsain 20U/ml) were added to the supernatant. Subsequently, we separated an ER 
vesicle-enriched P2 fraction (or "bound" fraction) by centrifugation 20,000 X g for 10 
min, from the S2, or "free" fraction. Deoxycholic Acid (DOC) was added to a final 
concentration of 0.5% (w/v) to S2 and to the resuspended P2, a further centrifugation 
20,000 X g for 10 min was performed to eliminate DOC-insoluble material, and the 
supernatants were loaded on linear 20 to 50% (w/w) sucrose gradients in 20 mM Hepes, 
pH 7.4, 150 mM KC1, 5 mM MgCl2. For the microarray assays, we did not fractionate 
separately S2 and P2; we added DOC directly to SI, spun 20,000 X g for 10 min and 
loaded the resulting "total" supernatant on the sucrose gradients. The gradients were 
centrifuged 200,000 X g in SW 41 rotors (Beckman) for 2 hrs. After the centrifugation, 
gradients were fractionated using an ISCO fractionator while monitoring the absorbance 
at 254 nm. 
RNA isolation and Oligonucleotide Array Expression Analysis: 
For microarrays analysis, pooled spinal cords and hindbrains from four Nova-1-null 
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animals were used for each replicate. As control, spinal cord and hindbrains from wild 
type or heterozygotes littermates were processed in parallel. One fifth of each lysate was 
used to directly extract the unfractionated "Total" RNA. Twelve fractions were collected 
from each gradient, and RNA obtained from three polysomal fractions, as judged by the 
UV254 absorption profile and by western blot with anti-PO ribosomal protein, was pooled. 
The RNA extraction was performed initially by Trizol extraction (Invitrogen), followed 
by a second purification and DNAse treatment step using the RNeasy kit (Qiagen). The 
yield of RNA from the pooled polysomal fractions was 15 to 20 |u.g on average. The 
synthesis of the probes for microarrays hybridization was performed as described at 
http://www.affymetrix.com. The purified RNA is initially reverse transcribed using a 
primer containing a 3' end oligo-(dT) and a 5' end T7 promoter sequence. Double 
stranded cDNA is then transcribed presence of biotinilated UTP and CTPs, producing a 
biotinilated cRNA probe, which is used for the hybridization. Hybridization and data 
collection was performed by the Rockefeller University Gene Array Resource Center. 
Data were initially collected in the Affymetric software MicroArray Suite, and then 
transferred to Gene Spring software (Silicon Genetics). To allow comparison between 
chips, the intensity value of each gene was normalized to the mean intensity value of 
entire chip. Each gene represented on the chips is associated with four sets of intensity 
values defined by the experimental parameters: wild type total, wild type polysomes, 
knock out total, knock out polysomes. Each set is made of three values, since the entire 
procedure was repeated three times. When comparing mRNAs in the polysome fraction 
between wild type and mutant, we normalized the intensity values in the polysome 
fraction to corresponding values in the total, to ensure that we were observing changes 
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that occurred specifically in the polysomes. 
Metabolic Phosphorylation assay: 
N2a cells growing in 10 cm diameter dishes in Dulbecco-modified Eagle medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) were transfected with 5 \ig 
of vector DNA encoding T7 tagged Nova-1 using 15 \xl of Fugene (Roche) according to 
the manufacturer's instructions. When cells reached 70% confluence, usually after 40 hrs 
incubation, the medium was substituted with Phosphate-free DMEM supplemented with 
Dyalized FBS. After one hour incubation in Phosphate-free medium, inorganic 32P to a 
final 0.5 mCi/ml was added to the dishes. After 5 hrs incubation at 37°C, the cells were 
harvested and lysed in 1 ml lysis buffer (1% NP 40, 0.5% DOC, 0.1% SDS, 0.15 M 
NaCl, 0.01 M Na phosphate pH 7.2, 2 mM EDTA, 50 mM NaF, 0.2 mM Na2OV4, 1 
complete protease inhibitor cocktail (Roche). Nova-1 was immunoprecipiated with 5 ]xg 
anti-T7 tag monoclonal antibody (Novagen) after a pre-clearing incubation with a pre-
immune mouse serum adsorbed to protein A beads. The pellet was washed five times 
with lysis buffer. After the second washing step, the pellet was resuspended in TBS 
containing 2 mg/ml RNaseA and 3,000 U/ml RNase Tl, and incubated 15 min at room 
temperature. After the last washing step, the pellet was resuspended in 2X SDS loading 
buffer, resolved by electrophoresis on SDS-PAGE, transferred to a nylon membrane and 
exposed to a radiography film. The identity of the bands observed by autoradiography 
was confirmed by western blot. 
Immunofluorescence of cell cultures: 
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For immunofluorescence of cell cultures, cells were plated onto chamber slides (Nalge 
Nunc), transfected where appropriate, and two days later rinsed with PBS, fixed (10 min 
in 2% paraformaldehyde in PBS at room temperature), washed, permeabilized (10 min in 
0.5% NP-40 in PBS at room temperature), washed again, blocked (1 hr at room 
temperature in PBG: 0.2% gelatin and 0.5% bovine serum albumin in PBS) and stained 
overnight with primary antibody in PBG at 4°C. After three washes in PBG, slides were 
incubated with fluorochrome-conjugated secondary antibodies in PBG for 1 hr at room 
temperature in the dark. Slides were then washed three times in PBG, once with DAPI in 
PBS, and once in PBS alone. Slides were left at room temperature to dry and then 
covered with mounting medium (Biomeda) and a coverslip (Fisher) before being sealed 
with nail polish. The slides were observed under multiple wavelength fluorescence from 
a mercury lamp (AttoArc), in an upright microscope (Zeiss Axioplan). Pictures were 
taken with a digital camera (Hamamatsu Orca), using Openlab software (Improvision) 
and presented with Photoshop software (Adobe). 
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C h a p t e r 3 
1) Role of Nova-1 in the regulation of alternative splicing: 
Introduction: In vitro RNA selection studies have identified the consensus 
sequence (UCAUY)3 as a high affinity binding target for Nova-1 recombinant protein 
(Buckanovich and Darnell, 1997; Jensen et al., 2000b). In an attempt to identify RNA 
sequences that Nova-1 binds in vivo, public databases and a compilation of neuron-
specific alternatively spliced exons and their surrounding introns (Stamm et al., 1994) 
were analyzed. Two candidate target sequences were identified in this way, both in an 
intronic location close to alternatively spliced exons. Only two potential Nova-1 in vivo 
RNA binding sites were initially identified, one within an intron of the Glycine Receptor 
al subunit (GlyRa2 ) pre-mRNA (Kuhse et al., 1991), and one in an intron of the Nova-
1 pre-mRNA itself (Buckanovich and Darnell, 1997). While these pre-mRNAs were 
shown to be indeed associated with Nova-1, by co-immuno-precipitation of the RNAs 
bound to Nova-1 followed by RT-PCR with specific primers, proof that the native Nova 
protein from mouse brain is able to directly bind the Gly R a2 intronic (UCAUY)3 
element was still lacking. 
Results: To address this question, a 90 nt intronic RNA surrounding the Gly R a2 
(UCAUY)3 element was transcribed in the presence of 32P-UTP, and ultraviolet (UV) 
cross-linked to proteins in brain extracts. As a control, we also transcribed a mutant Gly 
R a2 RNA, (UAAUY)3, previously shown not to bind Nova-1 in vitro (Buckanovich and 
Darnell, 1997) (Fig. IA). These mixtures were RNase treated, and Nova protein was 
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immunoprecipitated, run on SDS-PAGE gels, and transferred to nitrocellulose. A 32P-
labeled RNA band superimposable on the 55 kDa Nova protein band was seen 
specifically in immunoprecipitates of extracts cross-linked to the wild-type (UCAUY) 3 
but not the mutant (UAAUY) 3 RNA (Figure IB). This result demonstrates that native 
neuronal Nova protein specifically binds to the Gly R a2 intronic (UCAUY) 3 RNA. 
The location of the Nova-1 binding sites in introns in the proximity of 
alternatively spliced exons suggested the possibility that Nova-1 could modulate the 
alternative splicing of its target RNAs. We examined whether Nova-1 is able to directly 
act on GlyRa2 pre-mRNA to regulate alternative splicing of the E3A/E3B exons. We 
generated a minigene construct consisting of genomic DNA encoding GlyRa2 E2, E3A, 
E3B, and E4 and several hundred nucleotides of intronic DNA on either side of these 
exons (Figure 2A). To allow us to determine whether Nova-1 acts directly on the GlyRa2 
intronic (UCAUY)3 element, we also generated a mutant minigene in which this element 
was mutated to the nonbinding (UAAUY)3 sequence. These constructs were then 
transfected into three different cell lines along with increasing amounts of a plasmid 
expressing Nova-1 (pcNova-1). The total amount of DNA transfected in each well was 
normalized by transfecting appropriate amounts of empty vector DNA. 48 hours after 
transfection the RNA was extracted, reverse transcribed and amplified by PCR using 
primers specific to GlyRa2 E2 and GlyRa2 E4. Since the splicing products including 
exon 3a and exon 3b are exactly the same size, reaction products were digested with 
restriction enzymes that specifically recognized sites either in E3A (Sspl) or E3B 
(BspMI). We confirmed that these enzymes uniquely recognized E3A or E3B (with 
>98% specificity; data not shown). Nova-1 transfection mediated an increase in GlyRa2 
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E3A splicing in each of the three cell lines tested. Figure 2B illustrates the results of 
splicing assays performed on extracts of a neuroblastoma cell line, N2A, transfected with 
the wild-type (UCAU) or mutant (UAAU) GlyRa2 minigene in the presence or absence 
of pcNova-1. A Nova-1 dose-dependent increase in splicing to E3A (and compensatory 
decrease in E3B) is evident in cells transfected with the wild-type UCAU but not the 
mutant UAAU GlyRa2 minigene. We demonstrated that increasing amounts of pcNova-1 
vector led to increasing amounts of Nova-1 protein by Western blot analysis (Figure 2C). 
To confirm these results and analyze splicing to both E3A and E3B, we repeated 
independent transfection experiments in N2A cells (Figure 2D). In cells transfected with 
the wild-type UCAU GlyRa2 minigene, Nova-1 reproducibly mediated a two-fold 
increase of E3A splicing at the expense of E3B splicing. 
In N2A cells transfected with the mutant UAAU GlyRa2 minigene, splicing to 
E3A was unchanged relative to the wild-type minigene (Figure 2D). In the presence of 
increasing amounts of Nova, an increase in E3B, at the expense of E3A, was seen. While 
the mechanism underlying this observation is unclear, a possible explanation is that the 
UAAU mutation allowed detection of a cryptic Nova-1 binding site able to mediate an 
action on E3B splicing. Taken together, these results demonstrate that the action of Nova 
to enhance E3A utilization in wild-type UCAU GlyRcc2 pre-mRNAs was abolished by 
mutation in the intronic UCAU Nova-binding element. 
We repeated these experiments in HeLa cells and 293T cells, two non-neuronal 
cell lines that do not express Nova (Figure 2E and Figure 2F; data not shown). pcNova-1 
cotransfection with the wild-type GlyRa2 minigene mediated a 2.5-fold increase in E3A 
splicing in HeLa cells and a 2-fold increase in 293T cells. Some additional effects were 
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seen. In HeLa cells, the increase in E3A splicing was at the expense of E3B, while in 
293T cells the increase in E3A-spliced product was inversely proportional to a decrease 
in an aberrant spliced product that contained neither E3A nor E3B (E2-E4; data not 
shown). We also found that in cells transfected with the mutant UAAU GlyRo.2 
minigene, in the presence of Nova there was no increase in E3A splicing but again an 
increase in E3B splicing, and in the absence of Nova there was a small but consistent 
increase in E3A splicing that is unexplained. Taken together, these experiments 
demonstrate that Nova-1 is able to act directly to enhance the inclusion of GlyRa2 E3A 
in cell lines and that this action is dependent on the integrity of the intronic UCAU Nova 
binding site. 
The effects of transfected Nova on GlyRa2 minigene alternative splicing are in 
agreement with the effects of lack of Nova-1 on GlyRa2 splicing observed in Nova-1-
null animals (Jensen et al., 2000a). Nova-1 null mutant mice, generated by homologous 
recombination, are viable and phenotypically indistinguishable from their littermates at 
birth. Thereafter, they demonstrate progressive motor dysfunction and die an average of 
10-15 days after birth. Prior to their death, Nova-1 null mice exhibit an action-induced 
tremulousness and overt motor weakness, although they maintain normal responses to 
sensory stimuli. There is no abnormal phenotype in Nova-1 heterozygotes. Histologic 
examination and TUNEL staining of Nova-1 null mice revealed a 4-fold increase in the 
number of picnotic cells in the areas of the CNS expressing Nova-1 relative to littermates 
(Jensen et al., 2000a). 
Since GlyRa2 gene expression and physiology in rodent spinal cord and 
brainstem undergo regulation after the first week of postnatal life (Bechade et al., 1994; 
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Kuhse et al., 1991; Singer et al., 1998), GlyRa2 splicing was examined at various ages in 
Nova-1 null mice using RT PCR and RNAse protection assay. These studies 
demonstrated that the ratio of E3A/E3B splicing was decreased in Nova-1 null mice 
relative to wild-type littermates by 2-fold. Importantly, splicing defects in Nova-1 null 
animals were limited to spinal cord and hindbrain, the areas where Nova-1 is normally 
expressed (Jensen et al., 2000a). These results are consistent with our transfection data, in 
which Nova-1 acts to enhance the utilization of GlyRa2 E3A, while in the absence of 
Nova-1 in vivo there is a relative deficit in the ability of neurons to utilize the E3A splice 
site. 
2) In vitro assay of Nova action in alternative splicing: 
We sought to characterize the mechanism through which Nova achieves regulation of 
alternative splicing by establishing an in vitro assay. Attempts to recapitulate in vitro the 
alternative splicing pattern of GlyRa2 failed, probably due to the size of the four-exon 
construct and the complexity of the splicing choices (data not shown). We then turned to 
another target pre-mRNA, which emerged from the analysis of the Nova-1 null animals 
as a target for Nova-1 regulation. Alternative splicing of the GABAA receptor yl subunit 
(GABAARy2) was significantly altered in Nova-1 null mice (Jensen et al., 2000a). The 
GABAARy2 transcript is widely expressed in the brain, and the pre-mRNA is 
alternatively spliced to include the cassette exon 9 preferentially in brainstem and spinal 
neurons (Zhang et al., 1996). In Nova-1 null animals, the ratio between the exon 9-
including and exon 9-excluding forms (called L and S, respectively) was decreased three-
fold, suggesting a role for Nova-1 in promoting the inclusion of the alternative exon 
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(Jensen et al., 2000a). 
The effect of Nova-1 on GABAARy2 pre-mRNA has been further characterized 
by transfection of minigenes in heterologous cell lines (Dredge and Darnell, in press). For 
these studies, a modified version of SP64-H(3A6 (Krainer et al., 1984) was employed, in 
which the length of the middle exon was reduced to 24 nucleotides to attain a roughly 1:1 
ratio between the form including and the form excluding the alternative exon when the 
minigene was transfected in 293T cells. The second intron was also shortened. By 
inserting progressively shorter sequences from intron 9 of GABAARy2 in the second 
intron of this minigene, a sequence of 24 nucleotides was identified, that was able to 
confer Nova-dependent regulation of the inclusion of the alternative exon (Dredge and 
Darnell, in press). The 24 nucleotide Nova-dependent intronic splicing enhancer (NISE) 
contains four UCAU repeats, and their mutation to UAAU completely abolishes the 
Nova-1 effect on alternative splicing (Dredge and Darnell, in press). 
We resolved to utilize the two constructs Globin/GABA 1 and 2 to test the effect 
of Nova-1 in an in vitro splicing assay. Globin/GABA 1, containing 68 nucleotides of the 
GABAARy2 sequences, was the construct showing the most prominent effect of Nova-1 
in transfection, where the ratio between the long, alternative exon including form (L), and 
the short final product of splicing (S) increased around ten times in response to Nova co-
transfection (Dredge and Darnell, in press). Globin/GABA 2 is the construct containing 
the minimal 24 nucleotides NISE sequence necessary to enable a Nova-dependent effect 
on splicing. The ratio between the L product and S product increased around six times in 
response to Nova-1 co-transfection for the Globin/GABA B construct (Dredge and 
Darnell, in press). 
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Nova was purified as a fusion protein containing a six-histidine tag at its C-
terminus and a T7 tag at its N-terminus. Three sequential affinity chromatography steps 
were used in the purification protocol. The protein was initially bound to a Nickel column 
through its poly-Histidine tag, and then further purified using an immobilized monoclonal 
antibody against the T7 tag. A final ribohomopolymer poly(G) column was deployed to 
selectively recover protein still able to bind RNA after the acidic elution from the 
antibody column. The resulting fusion protein was almost 100% pure by Comassie stain 
(Fig. 3A) and able to bind its target RNA with high affinity and specificity (Fig. 3B). 
We performed in vitro splicing assays using HeLa nuclear extracts supplemented 
with purified recombinant Nova protein and body-labeled RNA. After 4 hrs of incubation 
the RNA was extracted and analyzed on a denaturing gel. The identity of the bands 
corresponding to the unspliced RNA, the two alternative products of splicing and exon 1 
(Fig. 4A and 5A) was defined by reverse transcription using an antisense exon 3 or 1 
primer, PCR amplification, cloning of the products and sequencing. Two substrates were 
initially tested, one corresponding to the globin/GABA 2 containing 24 nucleotides NISE 
and a mutated version in which the UCAU repeats were mutated in UAAU (Fig. 4B). The 
presence of recombinant Nova in the reaction mix reproducibly resulted in a dose-
dependent increase of the inclusion of the alternative cassette exon in the final product of 
splicing (Fig. 4A). The maximal increase is close to 2-fold and is observed with a Nova-1 
concentration around 0.12 uM (quantified by Bradford assay), or a molar ratio of Nova-
1:RNA of about 100:1 (Fig. 4C). Higher concentrations of Nova-1 in the reaction mix do 
not result in a further increase in the ratio between the long and the short product, which 
reaches a plateau and decreases (Fig. 4C and data not shown). Mutation of the GABA 
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NISE repeats results in the abolition of the ability of Nova-1 to promote inclusion of the 
alternative exon (Fig. 4C). 
In addition to these observations, we noted that a band migrating at an apparent 
size of around 260 nucleotides appears to dramatically increase in response to increasing 
concentration of recombinant Nova-1 in the reaction mix (Fig. 4A, indicated with a red 
star). The size of the band does not correspond to any of the predicted products or singly-
spliced intermediates of the splicing reaction. Furthermore, the in vitro splicing reaction 
of globin/GABA 1 substrate, which is completely identical to globin/GABA 2 but for 44 
more nucleotides of sequence derived from GABAARy2 (Fig 5A), results in an identical 
pattern of bands but for a band that becomes more prominent in a Nova-dependent 
fashion and migrates at an apparent size of more than 400 nucleotides (Fig. 5B, indicated 
with a blue star). The lack of correlation between the rate of migration of these two bands 
and difference in molecular size of the two RNAs suggests that they are lariats, spliced 
introns whose rate of migration is affected by the presence of a branching site (Ruskin et 
al., 1984). 
The identity of these two Nova-enhanced bands was determined by incubating the 
RNA eluted from the gel with S100 cytoplasmic extract from HeLa cells. S100 extract 
contains a 2', 5' phosphodiesterase or de-branching enzyme (Ruskin and Green, 1985). 
The de-branching activity of S-100 extract induces a shift in the apparent size of the 
aberrantly migrating bands: the band deriving from splicing of globin/GABA 2 shifts 
from an apparent size of 260 nucleotides to a size compatible with the second intron of 
globin/GABA 2, which is 181 nucleotides long (Fig. 6A, compare bands 3 and 4); the 
band deriving from globin/GABA 1 shifts from an apparent size of more than 400 
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nucleotides to a size compatible with the second intron of globin/GABA 1, which is 225 
nucleotides long (Fig. 6A, compare lanes 7 and 8). This assay also suggests that the bands 
migrating slower than the unspliced RNA correspond to the lariats including both the 
introns and the alternative exon that result from the skipping of the alternative exon in the 
splicing reaction (Fig. 6A, compare lanes 10 to 9 and 12 to 11). As a negative control, 
RNAs which do not contain lariats, the unspliced precursors, do not undergo any 
modification of their rate of migration in gel electrophoresis as a consequence of 
treatment with S100 extract (Fig. 6A, compare lanes 2 to 1 and 6 to 5). The apparent 
migration rate of lariat-containing RNAs is affected by the ratio between the sizes of the 
linear and the circularized portions of the molecule, and therefore by the position of the 
branching point (Grabowski et al., 1984). To determine whether part of the difference in 
the apparent rate of migration between the lariats observed in the globin/GABA 1 and 
globin/GABA 2 splicing reactions was due to the utilization of two different branching 
sites, induced by the insertion of GABAARy2 sequence of different length and 
composition, we mapped the branching point in the two lariat eluted from the gel by 
primer extension. The primer extension is stopped at the same site in the two lariats, 
demonstrating that the same branching point is utilized in the two constructs (Fig. 6B). 
Finally, the de-branched lariat from globin/GABA 2 was eluted from the gel, two RNA 
linkers were ligated at the 5' and 3' ends, reverse transcription and PCR amplification 
was performed using primers complementary to the linkers, the product was cloned and 
sequenced, identifying it as the precisely excised second intron (data not shown). 
The dose-dependent increase of the second intron lariat-product in response to 
Nova-1 protein suggests that the presence of Nova promotes the excision and/or the 
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stability of the second intron. The two actions (excision stimulation and stabilization) are 
not mutually exclusive, and it is difficult to discriminate between them, since an 
increased recruitment of splicing factors dependent on the presence of Nova on the 
second intron will eventually result in stabilization of the spliced intron. If splicing 
activation by Nova depends on an enhanced recruitment of splicing factors on the intron 
Nova binds to, interactions with constitutive splicing factors are expected. 
Previous yeast-two-hybrids screenings using Nova as a bait and libraries of 
embryonic and adult brain cDNAs as preys led to identification of a neuron-enriched 
PTB-like novel gene (Polydorides et al., 2000) and SRp20 (Yang et al., unpublished), 
among others, as interacting partners of Nova-1. The interaction with the PTB-like 
protein has been characterized in detail, and an antagonistic effect of brain PTB on 
splicing activation mediated by Nova has been demonstrated (Polydorides et al., 2000). 
The interaction with SRp20, which has been shown in several instances to act as a 
splicing activator (Cavaloc et al., 1999; Jumaa and Nielsen, 1997; Lim and Sharp, 1998), 
offers a potential mechanistic explanation for the activating effect of Nova-1 on exon 
inclusion. SRp20 is part of the large family of the SR proteins (reviewed in Graveley, 
2000), and the RS domain, consisting of repeats of Arginine and Serine residues, is found 
not exclusively in the SR protein family, but also in a number of other nuclear proteins, 
and it has been characterized as a protein-protein interaction motif (Graveley, 2000). In 
order to control the specificity of the interaction between SRp20 and Nova, we screened 
several members of the SR protein family and other SR-related proteins by yeast-two-
hybrid assay. Interestingly, some members of the SR proteins family, like SRp20 and 
9G8, and the SR-related U2AF65, Ul 70K and the U2AF65-interacting protein HUAP 
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56, were found to interact with Nova, while others, like SC35, ASF/SF2, SRp30c, SRp40 
and the SR-related protein U2AF35 did not (Fig. 7A). Nova-1 and the closely related 
Nova-2 were found to interact with the same set of proteins. 
The interaction of these proteins was assessed in mammalian cells by co-
transfection assays. 293 T cells were co-transfected with cDNAs encoding two isoforms 
of Nova-1 generated by alternative splicing (Nova-1 H+ and H-, see in the next sections) 
tagged with T7 and several proteins tested in the yeast-two-hybrid assay fused with GST. 
The cell lysate was RNAse treated and the GST fusion proteins were absorbed to GTT-
coated beads and the presence of complexes with Nova-1 was verified on western blot 
with antibodies against the T7 tag. As shown in figure 7B, the interaction of Nova-1 with 
U2AF65 (lane 3) and Ul 70K (lane 4) were confirmed in this assay, the interaction with 
HUAP 56 was confirmed in a separate set of experiments (data not shown). Surprisingly, 
the interaction with SRp20 was not confirmed in this system. The interaction with 9G8 
was not tested in this system. Furthermore, Nova-1 was shown to interact with itself in 
transfected cells (lane 1), in agreement with the structural studies in crystals and in 
solution (Lewis et al., 2000; Ramos et al., 2002), and with HuD, as previously shown 
(Okano and Darnell, unpublished). The recovery of T7-Nova-l was overall inefficient 
(<1% of the total T7 Nova). These data show that Nova-1 is capable of interactions with 
a subset of splicing factors containing RS domains although, given the limited set of 
potentially interacting proteins we considered, interactions with other factors are possible. 
The demonstrated association of Nova-1 with ninety nucleotides of the intronic 
sequence of GlyRa2 (Fig. 1) and the dose-dependent increase of the lariat product (Fig. 
5A) of globin/GABA constructs suggest that Nova first binds to the intronic sequence of 
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the regulated pre-mRNA. However, we have not directly verified if Nova-1 binds to the 
full-length pre-mRNA in the context of assembled spliceosomes, nor if it remains 
associated with intermediates or products of splicing. To address these issues, the 
antibody against the T7 tag was used to immunoprecipitate splicing complexes assembled 
in vitro either on globin/GABA B (Fig.8A, lanes 4 and 12) or globin/GABA mutated in 
the UCAU repeats (Fig.8A, lane 8). The positive control, anti-Sm monoclonal antibody 
Y12, recognizes the common Sm snRNPs (Lerner et al., 1981), and has been shown to 
immunoprecipitate pre-mRNAs, intermediates and products of various RNAs engaged in 
spliceosomes in vitro (Black et al., 1985; Chabot and Steitz, 1987; Chou et al., 1999; 
Grabowski et al., 1985). As expected, Y12 immunoprecipitates the unspliced pre-mRNA 
as well as intermediates and products of the splicing reactions of globin/GABA wild type 
and mutated (Fig. 8A, lanes 3, 7, 11). The protein A beads adsorbed with purified mouse 
IgG precipitate trace amounts of various RNA species (Fig. 8a, lanes 2, 6, 10). The anti-
T7 antibody, which in the absence of exogenous T7 tagged-Nova-1 does not precipitate 
RNAs above background levels (lane 4), efficiently precipitates various RNA species in 
the presence of recombinant Nova-1 (lanes 8 and 12). The precipitation of unspliced pre-
mRNA was nearly as efficient as with Y12 (compare lane 11 and 12) and the 
precipitation of intron 2 lariat product was more than three times more efficient in the 
wild type RNA reaction than in the mutant (compare lanes 8 and 12). These results 
indicate that Nova-1 is bound to the full-length pre-mRNA in the course of the splicing 
reaction. The immunoprecipitation of splicing intermediates indicates that Nova-1 is 
present in the pre-mRNA complexes containing the spliceosome, and it is not dissociated 
from its substrate during spliceosome assembly and the splicing reaction. Interestingly, a 
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sizable amount of the long product of splicing is recovered in the Nova-1 pellets. While 
the ratio between the long and the short product in the pellet of the Y12 
immunoprecipitation is exactly equal to the ratio between the two products in the total 
reaction (compare lanes 11 to 9 and 7 to 5, and Fig. 8b), there is an enrichment of the 
long form of almost two times in the pellet of the anti-T7 immunoprecipitation (compare 
lanes 12 to 9, and Fig.8b); the mutation of the Nova binding site in the second intron 
abolishes such enrichment (compare lanes 8 to 5, and figure 8b). 
3) Discussion: 
The results shown demonstrate that Nova is capable of affecting alternative 
splicing of artificial constructs in a way consistent with the results obtained in vivo in 
Nova-1-null mutant mice. Nova-1 present in brain extracts specifically cross-links the 
sequence (UCAUY)3 but not the mutant sequence (UAAUY)3, consistent with previous 
co-immunoprecipitation experiments demonstrating that Nova-1 protein binds GlyRa2 
pre-mRNA in vivo (Buckanovich and Darnell, 1997). In cotransfection assays, GlyRa2 
pre-mRNAs harboring this (UCAUY)3 sequence show a Nova-1 dose-dependent increase 
in utilization of the alternatively spliced E3A, while mutant pre-mRNAs harboring the 
(UAAUY)3 point mutant do not show this effect. In Nova-1 null mice, there is a 
reciprocal 2-fold decrease in the ratio of GlyRa2 E3A relative to E3B splicing (Jensen et 
al., 2000a). These data provide converging lines of evidence that Nova-1 regulates 
GlyRa2 splicing by directly binding to the pre-mRNA in neurons. 
Potential mechanisms for Nova action in alternative splicing regulation: The 
abolition of the effect of Nova on splicing by mutations of the Nova binding site both in 
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transfected cells and in vitro supports the notion that the binding of Nova-1 to its 
substrates is required for regulation of alternative splicing. Furthermore, the observed 
ability of recombinant Nova-1 to recapitulate in vitro the regulation of alternative splicing 
shows that at least part of the action of Nova is post-transcriptional and limited to the 
splicing step. In identified pre-mRNAs in which Nova-1 promotes the inclusion of an 
alternatively spliced exon, GlyRa2 and GABAARy2, the Nova binding site is situated in 
an intron 80 nucleotides upstream of a 3'splice site. While in the GlyRa2 case Nova 
binds to the intron preceding the exon whose inclusion is promoted by Nova, in the 
GABAARy2 pre-mRNA Nova binds to the intron downstream of the regulated exon. 
Thus, in the first example Nova binds an intron whose 3' splice site undergoes regulated 
splicing, while in the case of the second intron of GABAARy2 (and of GABA/Globin 
constructs) the 3' splice site is constitutively spliced and the 5' splice site is alternatively 
utilized (compare schemes in figures 2A and 4B). In both cases Nova-1 promotes the 
utilization of the alternative splice site more proximal to its intronic binding site. 
The search for basic components of the splicing machinery interacting with Nova 
resulted in factors that participate in the recognition of both 5' and 3' splice sites. Ul 70K 
is a component of Ul snRNP, whose snRNA anneals to the 5' splice site consensus 
sequence, and U2AF65 recognizes the polypyrimidine tract, close to the 3' end of the 
intron. These data suggest that Nova binds to specific sequences in the intron and recruits 
splicing factors through protein-protein interaction, stabilizing their interactions with the 
most proximal splicing sites and ultimately promoting the excision of the shorter version 
of the intron it is bound to. Consistent with this idea, in the only in vitro model available 
of a minigene regulated by Nova-1, the lariat product of the intron bound by Nova is 
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increased in a dose-dependent manner. After four hours of incubation in nuclear extract, 
the splicing products visualized in the urea PAGE are most probably the ones that were 
protected from the nucleases present in the extract because they were engaged in protein-
RNA complexes. The increase of the lariat product in response to Nova may result from 
two mechanisms: a) increased production (by increased splicing) and stabilization by the 
recruited U2/U5/U6 snRNPs or b) protection from nucleases through multimerization of 
Nova-1 from the initial high affinity binding site to cover the rest of the excised intron, 
analogously to the described behavior of Rev (Malim and Cullen, 1991), therefore 
independently of spliceosome recruitment. The second hypothesis does not seems very 
probable, since the interaction between Nova and its target RNA has always been found 
to be restricted to the UCAU repeats, when characterized with various RNAse protection 
techniques, even at very high protein/RNA ratios (Dredge and Darnell, unpublished). 
Furthermore, the excised lariat is precipitated also by anti Sm-antibody, suggesting that it 
is part of a complex with snRNPs. Therefore, although we have not directly demonstrated 
an increased level of spliceosomal complex formation in response to Nova-1, the simplest 
explanation for the increased levels of lariat product is that Nova stimulates the excision 
of the intron through recruitment of components of the spliceosome. 
While the enhanced recruitment of the spliceosome to the intron bound by Nova 
is a probable mechanism through which Nova regulates alternative splicing of target pre-
mRNAs, alternative scenarios cannot be ruled out at present. A construct made of the first 
and second (alternative) exons of the globin/GABA minigene fused together, followed by 
the second intron and the third exon, failed to show any enhanced splicing in response to 
increasing level of Nova in transfection and in vitro (data not shown). This lack of effect 
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may be due to the high efficiency with which this construct is spliced constitutively, 
probably due to the close match to the consensus sequence of both the splice sites, 
polypyrimidine tract and branch point. A second competing 5'splice site is required for a 
Nova effect to be observed in this artificial construct. In both the GABA/Globin artificial 
construct and in the GABAARy2 pre-mRNA, the 3' splice site of the first intron is weaker 
then the 3'splice site of the second, due to one and four purines, respectively, interrupting 
the polypyrimidine tract. An alternative way Nova could promote the inclusion of the 
cassette exon is by favoring the utilization of the weaker acceptor. This could be achieved 
by inhibiting the utilization of the constitutive 3'splice site, a mechanism opposite to the 
recruitment of components of the spliceosome we discussed above. A slower kinetic of 
the pathway leading to the exclusion of the alternative exon would unbalance the reaction 
in favor of the inclusion of the cassette exon. The described interaction of Nova with PTB 
and brPTB, a brain enriched gene similar to PTB (Polydorides et al., 2000), offers a 
possible mechanism for such inhibitory effect. However, this second hypothetical 
mechanism is difficult to reconcile with the GlyRa2 splicing regulation, where a slower 
kinetic of the utilization of the 3'splice site closer to the Nova binding site would lead to 
an increased inclusion of exon 3B, an opposite effect to what we observe in the presence 
of Nova. 
Interestingly, we observed that some Nova is also associated with the spliced 
product. Furthermore, there is specifically an enrichment of the long, exon-including 
form in the Nova pellet. While we have not directly tested if Nova is able to bind the 
exonic sequences of our construct, there are no obvious consensus Nova-binding sites in 
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the exons, nor they are created by the fusion of the exonic sequences by splicing. 
Therefore, the association of Nova-1 with the spliced product could result from 
interactions with the same components of the splicing machinery that Nova-1 helped 
recruit to the intron. The spliced products are indeed precipitated also by the anti-Sm 
antibody in our assay, suggesting that they are not completely disengaged from the 
splicing machinery. An alternative, albeit not incompatible explanation, is that Nova 
remains associated to the splicing product through interactions with components of the 
exon junction complex. The observed interaction between Nova and UAP56 provides a 
possible mechanism for such interaction. UAP56, a DEAD motif containing helicase, has 
been described as a factor coupling splicing and RNA export. UAP56 is required for 
interaction between U2 snRNP and the branchpoint (Fleckner et al., 1997), and it is 
eventually necessary for the recruitment of the mRNA export factor Aly to the spliced 
mRNP (Luo et al., 2001; Strasser and Hurt, 2001). Further experiments, in particular the 
purification of the mRNP through centrifugation on linear density gradient, are required 
to verify whether Nova is associated with the spliced RNA in the context of a mature 
mRNP. The "tagging" with Nova molecules of mRNA resulting from alternative splicing 
regulated by Nova could offer an interesting mechanism to couple nuclear events of RNA 
processing to the downstream steps of export, localization and translation. 
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Figure 1: Nova-1 protein from C N S lysates binds the predicted site in GlyRct2 
intron. 
(A) The 90 nt of GlyRa2 pre-mRNA sequence surrounding the Nova-1 binding 
consensus site. The mutations of the site are indicated in light blue. (B) An extract of 
mouse brainstem was incubated with the 90 nt 32P-labeled RNAs shown in A., encoding 
either the GlyR ct2 UCAU intronic sequence (lanes 1, 2) or mutant UAAU RNA (lanes 3, 
4). Samples were UV cross-linked, RNase treated, and immunoprecipitated with either 
rabbit anti-Nova serum (lanes 1, 3) or pre-immune serum (lanes 2, 4), run on SDS-PAGE 
gels and transferred to a filter for Western blot analysis with POMA antiserum. The same 
filter was also exposed directly to X-ray film to detect 32P-labeled RNA 
(Autoradiography). The arrow indicates the molecular size of Nova-1. The strong 
reactivity present underneath the Nova-1 bands (lanes 1-4) is due to secondary antibody 
cross-reactivity with rabbit immunoglobulin G. The ~70 kDa band visible in lanes 1 and 
3 is a protein related to Nova-2 that immunoprecipitates specifically with POMA 
antisera. 
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Figure 2: Nova-1 Enhances GlyRcc2 E 3 A Splicing in Heterologous Cell Lines. 
(A) The GlyRa2 minigene used for splicing assays in transiently transfected cells 
contains the complete GlyRa2 E2, a shortened intron 2, the complete genomic sequence 
surrounding E3A and E3B, a shortened intron 3, and 233 nucleotides at the 5' end of E4. The 
UCAU Nova-1 binding site in intron 2 is indicated by the schematic hairpin loop, and the UAAU 
mutant minigene is indicated by an X. 
(B) Nova-1-dependent effects on E3A splicing of the wild-type UCAU and mutant 
UAAU GlyRa2 minigenes. RNA from N2A cells transfected with the wild-type or mutant 
GlyRa2 minigene and the indicated amount of pcNova-1 plasmid were analyzed as in Figure 3 A. 
(C) Western blot using anti-T7 antibody showing the titration of T7-tagged Nova protein 
levels after N2A cells were cotransfected with the GlyRa2 minigene and the indicated amounts 
of pcNova-1. 
(D) Nova increases the ratio of E3A/E3B splicing from wild-type GlyRcc2 pre-mRNA, 
but this effect is abrogated in the GlyRct2 mutant UAAU pre-mRNA. Three independent 
transfections were performed in which splicing products (E3A or E3B) were quantitated as in 
Figure 3A. Increasing amounts of pcNova-1 were cotransfected with either the wild type or 
mutant GIyRa2 minigene, as indicated. Results are displayed as a ratio of E3A/E3B. The total 
amount of spliced product is unchanged as a result of Nova titration; the increase in E3A usage is 
accompanied by a compensatory decrease in E3B utilization (data not shown). Results shown are 
the average of three independent transfections, and error bars represent standard deviation. 
(E and F) Nova facilitates E3A splicing in HeLa (E) and 293T (F) cells specifically in 
wild-type UCAU GlyRa2 transcripts. Western blot confirmed that HeLa and 293T cells did not 
express Nova and that Nova transfection led to linear increases in Nova protein (data not shown). 
Results are the average of two (E) and four (F) independent transfections. 
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Figure 3: Scheme of purification of recombinant Nova-1: 
(A) Recombinant Nova-1 fused to a C-terminal poly-Histidine tag and a N-
terminal T7 tag was purified from transformed E.Coli through three affinity steps: Ni++ 
column, followed by anti T7 affinity column, and a ribohomopolymer column. Lane 1: an 
aliquot of the bacterial lysate. Lane 2: the eluted material from the Ni++ column; lane 3: 
the flow-through from the Ni++ column. An almost pure Nova was obtained by anti-T7 
affinity chromatography (lane 4), and it was further purified and concentrated by the 
binding to ribohomopolymer affinity step (lane 5). 
(B) Nitrocellulose filter binding assays were performed using Nova-1 fusion 
protein eluted from the ribohomopolymer column in 0.25 M NaCl and dialyzed against 
buffer D. GABA= in vitro transcribed RNA corresponding to the 150 nucleotides region 
of GABAARy2 intron 8 surrounding the Nova-dependent intronic splicing enhancer 
(Dredge and Darnell, in press). Globin= RNA derived from human P-Globin which spans 
a 150 nucleotides region of exon 1 and intron 1, and contains no YCAY motifs. 
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Figure 4: Nova-1 regulates alternative splicing in vitro: 
(A) 32P-labeled RNA products and intermediates of a splicing reaction in HeLa 
nuclear extract displayed on 8% denaturing gel. The reaction was carried out for 4 hrs in 
the presence of 0 (lanes 1, 2, 6), 0.06 (lanes 3 and 7), 0.12 (lanes 4 and 8) and 0.25 uM 
(lanes 5 and 9) recombinant Nova. The substrates, indicated on the top of the gel as WT 
and mut, are GABA/Globin 2 and GABA/Globin 2 mut (see panel B), body labeled with 
32P-otUTP. The identity of the indicated bands was established by RT PCR, cloning and 
sequencing. The red star indicates the lariat characterized in detail in figure 6. 
(B) GABA/Globin 2 substrate. The indicated cytidine residues were mutated to 
adenosine in the GABA/Globin 2 mut substrate. 
(C) Quantification of three different experiments performed on different days with 
different preparations of the substrates. The concentration of recombinant Nova is plotted 
in the x-axis; the ratio between the long and the short form normalized for the ratio 
observed in absence of added Nova is plotted in the y-axis. The red bars represent the 
ratio between the long and the short products in reaction containing the wild type 
substrate, the blue bars represent the same ratio in reactions containing the mutant 
substrate. The error bars represent standard deviations. 
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Figure 5: Formation of Prominent Nova-dependent products of splicing in vitro: 
(A) Schematic of the substrates used for in vitro splicing reactions. GABA/Globin 1 
and GABA/Globin 2 only differ for 44 nucleotides of GABAARy2 intron 8 
inserted in a globin-based backbone. 
(B) In vitro splicing reactions as in figure 4A using GABA/Globin 1 and 
GABA/Globin 2 as substrates. The stars indicate the bands from which RNA was 
eluted and analyzed in de-branching assay (see figure 6). The color code of the 
stars is the same as in figure 6. 
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Figure 6: Characterization of Lariat Products: 
(A) Debranching assay in HeLa cell S100 extract. The indicated bands (color code as in 
figure 5B) were incubated in S100 extract (lanes 2, 4, 6, 8, 10, 12) or buffer D (lanes 1, 3, 
5, 7, 9, 11). lanes 1 and 2: unspliced RNA 2, lanes 3 and 4: lariat product 2, lanes 5 and 6: 
unspliced substrate 1, lanes 7 and 8: lariat product 1, lanes 9 and 10: long lariat (cassette 
exon-skipping) 2, lanes 11 and 12: long lariat 1. 
(B) Mapping of the branch site by primer extension. A reverse transcription reaction was 
primed by a 32P-labelled oligonucleotide complementary to the 3'splice site and 
polypyrimidine tract of the second intron. The presence of a branching site interrupts the 
reverse transcription. Dideoxynucleotides were included in the RT mix in lanes 1, 2, 3, 4 
to produce a sequencing ladder. Lane 5, lariat product from 2 substrate, lane 6, unspliced 
2 substrate, lane 7, unspliced 1 substrate, lane 8, lariat product from 1 substrate. 
73 
A . 
• * 
Buffer D + . + . + . + . + . + . 
S100 . + . + - + - + - + . + 
420-
311-
249-
200-
1 51 
1 2 3 4 5 6 7 8 9 10 11 12 
B . 
A C G T ** * 
B r a n c h Point s e q u e n c e : 
U U U U G C U A U C A 
ddA ddCddGddT 
A 
A 
A 
A 
C 
G 
A 
T ,. 
- • 
/ 
A 
G 
T 
Antisense sequence 
1234 5678 
- • 
Figure 7: Nova-1 interacts with component of the splicing machinery. 
(A) Nova-1 and Nova-2 interactions with splicing factors. Nova-1 and Nova-2 bait 
constructs were used to screen a group of splicing factors prey constructs (a kind gift of 
David Elliot, Medical Research Council, Edinburgh). Colonies were screened for growth 
in medium lacking Histidine and X-gal assay. 
(B) Co-immunoprecipitation assay from 293T cells co-transfected with constructs 
encoding Nova-1, HuD, U2AF65, Ul 70K, SRp40, SRp20 fused to a N-terminal GST, 
and constructs encoding two isoforms of Nova-1 (with and without the 24 amino acid 
insertions encoded by the alternative exon H) fused to a flag tag. After cell-lysis, the 
protein complexes were precipitated with Glutathione-coated beads, washed several times 
and analyzed by western blot with anti-flag monoclonal antibody, but for the top panel, 
which was probed with anti-GST antibody. 
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Figure 8: Immunoprecipitation from in vitro splicing reactions: 
(A) Splicing reactions employing GABA/Globin construct 2 (lanes 1-4 and 9-12) and 
GABA/Globin construct 2 mutant (lanes 5-8) were incubated for 4 hrs at 30°C. At the 
end of the incubation, the indicated antibodies immobilized on protein A-beads were 
added, and the reactions were rocked for 1 hr. After three washes, the bound RNA was 
extracted and analyzed on a denaturing gel. 
(B) Enrichment of long product of splicing in the Nova pellet. The ratio long 
product/short product were measured in the immunoprecipitated pellets with anti T7 and 
anti Sm, and normalized to the same ratio in the input. 
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Introduction: Role of K H domain-containing R N A binding proteins in translation: 
It has been known for some time that several hnRNP proteins and SR proteins 
shuttle between the nucleus and the cytoplasm (Caceres et al., 1998; Pinol-Roma and 
Dreyfuss, 1992). These findings, and the discovery of the exon junction complex, primed 
a series of studies aiming to demonstrate a connection between the nuclear history and 
the fate of messages in the cytoplasm (Dreyfuss et al., 2002; Keene and Tenenbaum, 
2002; Matsumoto et al., 1998; Shyu and Wilkinson, 2000; Tenenbaum et al., 2000). Nova 
has been shown to be present both in the nucleus and in the cytoplasm in brain sections 
and in primary neurons in culture (Buckanovich et al., 1993; Buckanovich et al., 1996; 
Yang et al., 1998), and a Leucine-rich region resembling a NES domain is present in both 
Nova-1 and Nova-2. 
Nova is closely related to three shuttling hnRNPs, hnRNP K, El and E2, which 
have been shown to play a role in the cytoplasmic fate of their RNA targets. HnRNP K 
represses the translation of 15-lipoxygenase (LOX), a key enzyme involved in 
mitochondrial membrane breakdown during erythroid cell differentiation. The expression 
of this enzyme, which is potentially extremely toxic in normal cells, must be tightly 
regulated during the course of erythroid cell maturation, while the cell is still relying on 
its mitochondria for energy, before it is released in the peripheral blood to become 
reticulocyte and erythrocyte. Such control is achieved through the binding of hnRNP K 
and El, 2 to an UC-rich element (CCUCUU repeats) in the 3'UTR of the LOX message, 
called Differentiation-Control Element (DICE). The binding of hnRNP K to the 3'UTR 
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masks the message from the translational apparatus. In particular, hnRNP K bound to 
DICE has been shown to inhibit the assembly of the two subunits of the ribosome at the 
5' end of the mRNA, in a process that presumably involves the circularization of the 
message (Ostareck et al., 2001; Ostareck et al., 1997). Interestingly, hnRNP E (also 
called ctCP) is also implicated in stabilization and, ultimately, increased expression, of a 
different message, a-globin, through the binding to a C-rich motif present in the 3'UTR. 
The protein is found to be part of the RNP "cc-complex", which is compatible with 
efficient polysome loading and active translation (Ji et al., 2003). Other KH-domain 
containing proteins have been implicated in translational control and have been found to 
be associated with polysomes. FMRP, the product of the gene responsible for most 
Fragile X chromosome Mental Retardation cases, is associated with polysomes in several 
cell lines (Khandjian et al., 1996), while some of the cellular FMRP seems to be part of 
pre-polysomal mRNPS (Feng et al., 1997). More recent studies have defined a restricted 
subset of FMRP-targeted mRNAs and further demonstrated that the absence of FMRP 
results in an increase and a decrease of two distinct subsets of mRNAs in the actively 
translating polysome fraction (Brown et al., 2001; Darnell et al., 2001). The results of 
Brown et al. suggest that FMRP controls some aspect of translation, although the precise 
mechanism of such regulation is entirely undefined at the moment. Other, less well 
characterized KH-domain containing proteins, like SCP 160 in S. cerevisiae and CRD-
BP, a protein that binds to the c-myc coding region, have also been shown to be 
associated with polysomes (Doyle et al., 1998; Lang et al, 2001) 
A clue on the potential cytoplasmic role of Nova came from the results of a 
"transcribed sequence selection" (TSS) experiment in which recombinant Nova was used 
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to select target sequences out of a pool of transcribed R N A s (Jensen and Darnell, 
unpublished). Among other target sequences isolated with this approach, there was a 
distinct population of transcribed RNAs containing a 50 bp stretch of RNA present in 
domain IV of 28S ribosomal RNA. Domain IV is one of the most exposed sequences 
found in 28S rRNA and in the intact 60S ribosomal subunit, as determined by chemical 
probing and X-ray diffraction crystallography (Ban et al., 2000; Holmberg et al., 1994a; 
Holmberg et al., 1994b), and it is therefore likely to be accessible to protein binding in 
vivo. Immunocytochemical studies performed in brain slices and in primary neurons have 
shown that Nova distributes in the cytoplasm in rather discrete granules that are 
heterogeneous in size. Partial co-localization of Nova and P0 ribosomal protein in the 
cytoplasm and dendrites was observed (Triller and Darnell, unpublished). 
Nova distribution on linear density gradients: 
To gain insight into the function of Nova in the cytoplasm, we fractionated post-
mitochondrial cytoplasmic extracts on linear density gradients. We analyzed cytoplasmic 
extract from N2A and PI9, two cell lines that express Nova, and from spinal cords and 
hindbrain of mice at different ages. The profile of sedimentation of Nova-containing 
structures shows some variability between cell lines and tissue, and between extracts 
from tissues at different ages. In N2a cells (Fig. 9) and in P19 cells differentiated into a 
neuron-like phenotype with retinoic acid (not shown), 50% of Nova was found in the first 
two fractions of the gradient, probably corresponding to protein not engaged in large 
complexes. 70% of the total content of Nova, as estimated by densitometry, sediments in 
fractions lighter then those containing the 80S ribosomal monomer (fractions 1 to 8), and 
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only very small amounts are seen in the fractions corresponding to polyribosomes. The 
treatment of the extracts with 30 mM EDTA, which results in the disruption of 
polysomes (right panel of figure 9), did not change the profile of sedimentation of Nova, 
nor did treatment with RNAse A (not shown). These data show that in the cytoplasm of 
the analyzed cell lines, most Nova is not engaged in the formation of large complexes. As 
a control, the same blots were re-probed with a monoclonal antibody against FMRP, a 
protein known to be largely associated with polysomes in various cell lines (Feng et al., 
1997; Khandjian et al., 1996). As shown in figure 9, a considerable fraction of FMRP 
(36% as estimated by densitometry) associates with polyribosomes (fractions 13 through 
18); the disruption of the polysomes by 30 mM EDTA treatment results in a sizable shift 
of FMRP to the upper half of the gradient (figure 9, right panel). 
Most of the observations that suggested co-localization of Nova and P0 ribosomal 
protein were obtained in primary neurons, and increased co-localization and more 
discrete Nova-positive granules were observed after three to four weeks in culture (Triller 
and Darnell, unpublished). Therefore, we analyzed the distribution of Nova on linear 
density gradients in neural tissue from animals at three (P3), fourteen (P14) and thirty 
days (P30) of age. The tissue was obtained from spinal cord and hindbrain, where Nova-1 
is the predominant Nova species. After homogenization, nuclei and non-lysed cells were 
removed by a low speed centrifugation step. The supernatant was further fractionated 
with a higher speed centrifugation step (20,000Xg, 10 min) to obtain a pellet enriched in 
vesicles of the rough endoplasmic reticulum, as shown by the staining with an antibody 
against Riboferin I (Fig. IOC) a transmembrane glycoprotein specifically associated with 
the rough endoplasmic reticulum (Kelleher and Gilmore, 1997; Silberstein et al., 1992). 
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Nova is more than three times more abundant in the supernatant than in the pellet 
obtained in this centrifugation step (Fig. IOC). Vesicles were solubilized with 
deoxycholic acid, and residual insoluble structures were discharged through a further 
centrifugation step. The supernatants were then fractionated on linear density gradients. 
When the supernatant of the 20,000Xg centrifugation (S) was analyzed by linear 
density gradient, a large fraction of Nova (around 40% of the total, by densitometry) 
sediments in the first two fractions, corresponding to the lysate layered on the top of the 
gradient (Fig.lOA). This fraction probably corresponds to monomeric Nova, or Nova not 
engaged in large complexes. 78% of the total amount of Nova sediments above the 80S 
ribosome (Fig.lOA). The treatment with 30 mM EDTA does not result in a major change 
of the Nova profile of sedimentation (Fig. 10A, right panel), although it does cause a shift 
of the ribosomes from the bottom part of the gradient to the upper part, following the 
disruption of the polysomes (Fig. 10A, P0 lane, right panel). When we analyzed the Pellet 
(P) of the 20,000Xg centrifugation, a smaller fraction of Nova was found in the top 
fractions of the gradient, not surprisingly, since the majority of the proteins that are not 
part of large complexes are expected to be found in the S fraction. Around 50% of the 
Nova reactivity is found in the fractions above the 80S ribosome monomer, and 20% 
sediments in the lower part of the gradient, in the fractions where polysomes are found 
(Fig.lOB). Again, the treatment with 30 mM EDTA does not dramatically modify the 
overall distribution of Nova on the gradient. 
The analysis of extracts from fourteen day old animals shows a similar profile, 
with around 60% of Nova found in fractions above the 80S, and 20% of Nova in the 
polysomal fractions, in both supernatant and pellet fractions (data not shown). 
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In one month old animals, a fraction of Nova variable between 17 and 3 0 % of the 
total (in the supernatant and pellet fractions, respectively), is found to sediment in the 
lower part of the gradient (fractions 13 to 18, polysomal fractions). EDTA treatment 
shifts 77% of the pool of Nova associated with polysomes (from 17.4% of the total 
reactivity for Nova by densitometry to 3.9% in the "free" polysomes fraction) to the 
upper part of the gradient, coincidentally with the expected shift of the ribosomes 
detected with the anti-PO serum (Fig. 1 IA and C). 
As a comparison, we stained the same blots with a human polyclonal antibody 
against Hu (Okano and Darnell, 1997). The pattern of sedimentation of Hu proteins in 
gradients of Accudenz and Glycerol has been characterized in various tumor cell lines of 
neural origin (Antic and Keene, 1998). While some of the cytoplasmic Hu is found in a 
free state, a variable amount is engaged in the formation of large heterogeneous 
ribonudeoprotein complexes (a complexes), and around twenty per cent of the total is 
associated with polysomes (|3 complexes)(Antic and Keene, 1998). In our tissue extracts, 
the distribution of Hu reactivity matches quite closely the distribution of Nova. At P3 
most of Hu is part of large, heterogeneous complexes, that coincide with the a complexes 
described in previous studies (Antic and Keene, 1998), and the treatment with EDTA 
only marginally modifies the pattern of sedimentation. At P30 more than twenty percent 
of the Hu sediments in the denser part of the gradient and the treatment with EDTA 
determines a shift to less dense fraction, coincidentally with the disruption of polysomes 
(Fig. HAtoB). 
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Changes in the level of expression of genes in the absence of Nova: 
In an attempt to expand our understanding of the variations in gene expression underlying 
the Nova null phenotype, mRNAs from mutant animals and their wild-type or 
heterozygote littermates were purified and utilized to probe microarrays. The position of 
a given mRNA in a linear density gradient can be attributed to the number of associated 
ribosomes. The number of ribosomes per mRNA reflects the translational efficiency of 
the mRNA, unless the ribosomes are stalled or translation is inhibited in the elongation 
phase. An mRNA that is poorly or not translated will typically accumulate in the mRNP 
or "monosome" (80S) fraction of the gradient; translationally active mRNAs will 
sediment in the polysome fraction (reviewed by Carter, M.S. et al., 2000). To 
specifically identify differences at the translational level, we compared absolute levels of 
mRNAs and abundance of mRNA specifically in the polysome fraction. For each 
experiment, post-mitochondrial supernatant obtained from four pooled spinal cords and 
hindbrains was fractionated on a linear 20 to 50% sucrose gradient and the mRNA 
associated with each fraction was purified (Fig. 12A). One fifth of the total volume of 
extract was not fractionated; mRNA was directly purified as the "total" fraction. The 
purified mRNA from the input and polysome fractions was utilized to generate cDNA 
first, using an oligo(dT) containing the T7 promoter sequence as primer, which allowed a 
further transcription step in presence of biotinylated nucleotides to generate the cRNA 
used to probe the microchips (Fig. 12B). We probed the three Affymetrix Murine 
Genome Array U74 chips covering approximately 36,000 full-length mouse cDNAs and 
EST clusters from the UniGene database (www.affymetrix.com). The experiment was 
repeated three times, resulting in three intensity values for each gene represented on the 
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chips for the total (mutant and wild type) and three intensity values for the polysomes 
fraction (mutant and wild type). 
We first verified the efficacy of our fractionation procedure by comparing the 
abundance of mRNAs in the total fraction (independently of the genotype) with the 
polysome fraction. We performed a t-test analysis between the pool of six values of the 
total fraction (three wild type and three mutant) and the corresponding six values of the 
polysome fraction for each gene represented in the chips, using GeneSpring 5.0 software 
(Silicon Genetics) (Fig. 13). A number of genes appear to be more abundant in the total 
than in the polysome fraction. Ten cDNAs, among which glyceraldehyde-3-phosphate 
dehydrogenase and beta actin, are enriched in the polysomes, consistently with a high 
rate of translation. A number of cDNAs encoding ribosomal proteins are two to four fold 
more abundant in the total fraction than in the polysomes, consistently with previous 
findings (Table I)(reviewed in Meyuhas and Hornstein, 2000). mRNAs encoding ferritin, 
whose expression is also regulated at the level of translation, were similarly distributed. 
To compare differences specifically in the polysome fractions between wild-type 
and Nova-null mice, the set of values corresponding to the polysome-associated mRNAs 
was normalized to the corresponding set of values obtained with the total probe. A r-test 
analysis detected statistical differences between the two sets of polysome-associated 
mRNAs normalized to their corresponding input values. The intensity of sixty-seven 
genes that showed equivalent level in the total fraction was statistically different between 
wild-type and mutant polysomes (p<0.05) (Fig. 14). These genes were grouped into two 
groups based on whether they were decreased or increased in the polysomes of Nova-1 
null mice. Thirty-nine messengers were found to be less represented in the pool of the 
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polysome-associated m R N A s from Nova-null mice (table II), while twenty eight were 
increased (table III). 
Discussion: 
Several RNA binding proteins are found both in the nucleus and in the cytoplasm 
and play different roles in RNA metabolism in the two compartments (reviewed in 
(Dreyfuss et al., 2002). In an attempt to understand the function of the cytoplasmic pool 
of Nova, we began the characterization of the cytoplasmic complexes that contain the 
protein. Our results show that an amount of Nova variable between cell lines and tissues 
from animals of different ages is involved in large heterogeneous complexes, which are 
stable in presence of EDTA. Only in extract from animals older than three weeks, around 
one fifth of the total amount of Nova detected by western blot sediments in the same 
fractions as polyribosomes formed by four or more ribosomes, and it is shifted to less 
dense fractions in response to EDTA treatment. The size of these later complexes and 
their dependence on divalent cations suggest that they represent Nova associated with 
polyribosomes. 
The large heterogeneous complexes containing Nova, not dependent on divalent 
cations, as shown by their resistance to EDTA treatment, are reminiscent of the a-
complexes containing FMRP, Hu or aCP (Antic and Keene, 1998; Feng et al., 1997; Ji et 
al., 2003). These complexes are described as mRNPs, but their exact composition and the 
relationship between proteins and RNA within them are largely unknown. It is postulated 
that mRNAs are tightly packed with protein components of the mRNPs, since the 
complexes are completely or partially resistant to RNAse treatment (Ch'ng et al., 1990; 
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Feng et al., 1997; Herrera et al., 1988), and very prolonged treatments with RNAse are 
required for their disruption (Antic and Keene, 1998). Treatments with RNAse A 
sufficient to disrupt the polyribosomes did not result in shift of the Nova complex to less 
dense fractions (data not shown), suggesting that either the Nova-positive complexes we 
observed do not contain RNA, or that the RNA contained in them is not exposed to the 
RNAse action. Since we have evidence that Nova is associated with poly(A)+ RNA in 
the cytoplasm (Triller and Darnell, Dunne and Darnell, unpublished) we are inclined to 
consider the second explanation as more probable, although the possibility that Nova can 
be engaged in large complexes not containing RNA can not be disregarded. 
Most of the studies aimed to characterize the cellular structures RNA binding 
proteins are engaged in, such as mRNPs and polyribosomes, have been conducted in 
immortalized cell lines, rather than in extracts from differentiated tissues. Given the 
complex relationships between mechanism of gene expression, cell cycle and 
differentiation, it is not surprising that RNA binding proteins are part of complexes of 
different size and functional state across different cell lines and tissues. The differences in 
the Nova sedimentation pattern we observed between neuroblastoma cells and spinal 
chord tissue, and between spinal chord tissues of different ages, may underlie changing 
functional roles of Nova in various physiological states. The heterogeneous structures in 
which most of Nova is engaged could represent sites of storage or transport of mRNAs 
whose translation requires a tight regulation in time or in space. The later association of 
some Nova with polyribosomes could be due to the activation of the translation of some 
of the mRNAs Nova is bound to, possibly as a consequence of some maturation event in 
the nervous system. 
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Hu is a family of four R N A binding proteins found in the nucleus and cytoplasm. 
HuA(also called R) is ubiquitously expressed, while HuB, HuC, and HuD are exclusively 
expressed in neurons. A role in regulation of alternative splicing have been demonstrated 
for their Drosophila homolog ELAV1 (Koushika et al, 1996; Koushika et al., 2000; 
Lisbin et al., 2001). Hu family members bind poly(A)+ RNA in the cytoplasm (Gallouzi 
et al., 2000; Gao and Keene, 1996). Described cytoplasmic Hu functions include 
stabilization of messages containing AU-rich elements (ARE) in their 3'UTR, and 
stimulation of translation of specific messages (Antic et al., 1999; Brennan and Steitz, 
2001; Fan and Steitz, 1998). Hu has consistently been found to be engaged in 
heterogeneous mRNPs in several cell lines, and to be associated with polysomes in a 
proportion variable on the cell type (Antic and Keene, 1998; Gallouzi et al., 2000; Gao 
and Keene, 1996). We report the first analysis of the Hu sedimentation in CNS extracts. 
Interestingly, the pattern of sedimentation of Hu in spinal chord and hindbrain extracts 
matches closely the one of Nova: Hu sediments with large heterogeneous structures, 
presumably mRNPs, throughout the development time points we analyzed, and some Hu 
is found in the polysome fractions, most visibly in extracts from one month or older 
animals. Hu has been found to form with Nova an RNAse-resistant complex (Okano and 
Darnell, unpublished, and Fig. 7B). It is therefore possible that in spinal chord 
cytoplasmic extracts, Hu and Nova are present in the same mRNP and regulate the 
expression of an overlapping set of messages. 
We utilized the fractionation of cytoplasmic extracts from neural tissue on linear 
density gradients to begin to identify genes whose translational state is changed in the 
absence of Nova-1. While a similar approach has been utilized to analyze extracts from S. 
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cerevisiae and a number of replicating cell lines (Arava et al., 2003; Brown et al., 2001; 
Galban et al., 2003; Grolleau et al, 2002; Johannes et al., 1999; Zong et al., 1999), this is 
the first such analysis on extracts from fully differentiated neural tissue. This strategy is 
of obvious relevance for the study of aspects of translation that are thought to be peculiar 
of mature neurons, such as dendritic translation. The reliability of our data set was 
validated by the finding that several mRNAs encoding ribosomal proteins were found 
decreased in the polysome fraction compared to the total. The synthesis of many 
mammalian ribosomal proteins has been shown to be selectively regulated in a growth-
dependent manner at the translational level. The corresponding mRNAs are characterized 
by the presence of a 5'-terminal oligopyrimidine tract (5TOP) and therefore are referred 
to as TOP mRNAs. The proportion of TOP mRNAs actively engaged in protein 
synthesis, and therefore associated with polysomes, is significantly lower than that 
characteristic of other ubiquitous mRNAs in cells that cease to divide, as most of the cells 
in the spinal cord, than in actively replicating cells (reviewed by Meyuhas and Hornstein, 
2000). 
We identified sixty-seven genes whose distribution in the polysomes is increased 
or decreased in response to the ablation of Nova. Although further experiments are 
required to verify that the observed shift of mRNAs in the linear gradient reflects changes 
of protein synthesis, the identity of some of the messengers identified with this approach 
provides some clues on cellular functions that are altered as a direct or indirect 
consequence of the deletion of Nova. The described functions of a group of six genes, 
four of which are decreased in absence of Nova, and two increased, can be loosely 
referred to the mechanisms connecting receptors and cytoskeleton in the post-synaptic 
87 
densities through clustering molecules and the signalling cascades mediated by ras 
monomeric GTPases. CNK (connector enhancer of ksr) has been originally described in 
Drosophila as a modifier of Kinase suppressor of ras (ksr), a required component within 
the RAS/MAPK cascade (Therrien et al., 1998)). CNK is a large protein containing a 
variety of potential protein-protein interaction modules: a sterile alpha motif (SAM) 
domain, a PDZ domain, a pleckstrin homology domain (PH), a so-called CRIC domain 
(Conserved Region in CNK) two proline-rich stretches that fit the consensus for SH3 
domain binding site, and several potential tyrosine phosphorylation sites (Therrien et al., 
1998). It has been proposed to act as a multiadaptor molecule by binding and probably 
inhibiting RAF (MAPKKK) while enhancing Ras signaling in Drosophila (Therrien et 
al., 1999). Studies in rat have shown that Maguin, the rat homolog of CNK, interacts with 
Postsynaptic density PSD-95 (SAP 90), a major component of the post-synaptic densities 
with a role in clustering receptors and channels and in signal transduction (Yao et al., 
1999). Interestingly, the level of mRNA encoding DAP-1 (GKAP), a highly brain-
enriched protein also known to form a complex with PSD-95 (Kim et al., 1997; Satoh et 
al., 1997), is decreased in the polysome fraction of the Nova-null animals. mRNAs 
encoding Rho GTPase activating protein 6 and ras-j were also decreased in the 
polysomes in the absence of Nova. Members of the Ras family of monomeric GTPases 
play a major role in the signal transduction from receptors associated with post-synaptic 
density. SynGAP is associated with PSD-95 in many glutamatergic synapses, citron (a 
rho/rac effector protein), and synaptic gpl30 Ras GAP have been the detected as part of 
post-synaptic densities (Kennedy, 1998; Kennedy, 2000). Furthermore, regulation of 
remodeling of the actin cytoskeleton by Rho GTPases is essential for the formation of 
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post-synaptic specializations, like dendritic spines, and yet another protein encoded by 
one of the mRNAs whose distribution is modified in the absence of Nova, filamin, plays 
a crucial role in the modulation of the functional proprieties of filamentous actin in 
dendritic spines (van der Flier and Sonnenberg, 2001). The simultaneous alteration of the 
distribution on polysomes of messengers encoding functionally related proteins in 
response to the absence of Nova suggests that disruption of organization of post-synaptic 
densities or dendritic spines, through alteration of the clustering complexes or the ras-
mediated pathways may be implicated in aspects of the Nova-1-null phenotype. 
Simultaneous changes of abundance in the polysomes are also observed for a 
group of three mRNAs encoding metalloproteases, and three mRNAs encoding 
transcription factors. No obvious functional relationship is evident among the members of 
these two groups. 
89 
Figure 9: Analysis of cytoplasmic extracts from N2a cells on linear density 
gradients: 
A cytoplasmic extract from N2a cells was analyzed by sedimentation on a linear density 
gradient. 
For (A) and (B), the top panel shows the absorption profile of a 20%-50% (w/w) sucrose 
gradient at 254 nm, with major ribosomal peaks indicated; the bottom panel shows the 
distribution of Nova, FMRP and ribosomal protein PO in correlation to the sedimentation 
profile. Fraction numbers are indicated underneath the corresponding lanes. 
(A) The cytopasmic extract was prepared and sedimented in the presence of 5 mM 
MgCl2. 
(B) Polysomes and ribosome monomers are disrupted by EDTA. 
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Figure 10: Analysis of polysomes from P3 spinal cords and hindbrains. 
Spinal cords and hindbrains from P3 animals were homogenized and a cytoplasmic 
extract was extracted. After eliminating nuclei with a low speed centrifugation, the 
extract was fractionated by centrifugation at 20,000 X g yielding a supernatant ("free") 
fraction and a pellet enriched in rough endoplasmic reticulum. The pellet was solubilized 
("bound") with deoxycholic acid, and both fractions were analyzed by centrifugation on a 
linear density gradient. 
(A) Western blot analysis of the collected fractions of the sucrose gradient where the 
"free" fraction was loaded. Antibodies against Nova, Hu, P0 were employed. 
(B) Western blot analysis of the collected fractions of the sucrose gradient where the 
"bound" fraction was loaded. Antibodies against Nova, Hu, P0 were employed. 
(C) An aliquot of the "free" and "bound" fraction was analyzed by western blot with 
antibody against ribophorin, a marker of the endoplasmic reticulum, and antibody against 
Nova. 
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Figure 11: Analysis of polysomes from P30 spinal cords and hindbrains. 
Extracts from spinal cords and hindbrains of P30 animals were prepared as in figure 11 
and analyzed on linear density gradient as described. 
(A) Analysis of the "free" polysomes. 
(B) Anlysis of the "bound" polysomes. 
(C) Quantification by densitometry of the bands reactive to Nova in western blot of linear 
density gradient fractions shown in (A). The blue bars indicate the values of the Mg 
fractions, the red bars indicate the EDTA fractions. 
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Figure 12: Scheme of the analysis of the polysome-associated m R N A s in wild type 
and Nova-null mice: 
(A) Sucrose gradient fractionation of total cytoplasmic extracts from P7 spinal cord and 
brainstem. The top panel shows the absorption profile of the sucrose gradient. The 
polysome fractions are indicated. The bottom four panels show the distribution of Nova 
and PO ribosomal protein by Western analysis of the fractions from two sucrose gradients 
on which extracts from wild type and Nova-1 null tissues were loaded. The residual 
bands reacting with the anti-Nova antibody in the KO row correspond to Nova-2. 
Fraction numbers are indicated below the corresponding lanes, and fractions 9-11, used 
for microarray analysis, are underlined. 
(B) Synthesis of the biotinilated probes for Affymatrix microchips hybridization. The 
RNA collected from the indicated fractions or from the total was reverse transcribed 
using primers containing a stretch of oligo(dT) at their 3' end and a T7 promoter 
sequence at their 5'end. The cDNA resulting from this reaction is then transcribed using 
T7 promoter in presence of Biotin, producing the biotinilated cRNA probe that is used for 
the hybridization of the microarrays. 
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Figure 13: Comparison between the total and polysome fraction (validation of the 
fractionation procedure): 
Four sets of intensity values were obtained for each gene from the hybridization of 
microarrays. Each set is defined by Genotype and Fraction (WT tot, KO total, WT 
polysomes, KO polysomes), and contains three intensity values (replicates) per gene. In 
the comparison between total and polysome fractions, shown in this figure, the sets were 
pooled by Fraction. Therefore, two sets (Total and Polysome) with six values of intensity 
each to each gene correspond. A Mest was run between the Total and the Polysome sets 
for each gene. The graph shows the intensities of those genes for which the two sets of 
values (total and polysome) were found to be different (p<0.001). The y-axis represent 
the intensity values expressed in logarithmic scale, normalized by the mean intensity of 
each chip. The x-axis lists the four experimental conditions. For each gene, a colored line 
joins the four intensity values (each of which is the mean of three replicates) across the 
four experimental conditions. 
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Table I: 
List of genes that show different relative intensity in the Polysome fraction and the Total 
(p<0.001). Yellow rows indicate genes encoding ribosomal proteins. Light blue rows 
indicate genes encoding ferritin. 
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LESS ABUNDANT IN THE POLYSOME FRACTION THAN IN THE TOTAL 
protein tyrosine phosphatase 4a3 
Mus musculus, clone IMAGE: 1379146. mRNA, partial cds 
ribosomal protein S12 
qrowth arrest specific 5. encodes U75 and U76 snoRNAs 
t-complex testis expressed 1, dvneln llqht chain (microtubule associated transport) 
ribosomal protein L41 
RIKEN cDNA 3200001M24 qene 
epimorphln 
unknown; 
svnapsin I actin bindlnq synaptic vesicle 
translocase of Inner mitochondrial membrane 9 homoloq (yeast) 
RIKEN cDNA 2400008104 qene 
hexokinase 1, deficiency causes hemolytic anemia 
ribosomal protein S26 
RIKEN cDNA 2900010M23 qene 
thymosin, beta 10 
ESTs, Weakly similar to RIKEN cDNA 2010000G05 
Mus musculus. Similar to chromosome 9 open readinq frame 16, clone MGC: 19388 
ribosomal protein L27a 
RIKEN cDNA 3110005M08 qene 
ribosomal protein L28 
ESTs 
DIGeorqe syndrome critical reqlon qene 6, development, schizophrenia 
cyclin I 
ribosomal protein S28 
Mouse qene for ferritin H subunit. 
neuronatln, exp In neonates>adults, expressed in VP cells of rat supraoptic nucleus 
SEC61, qamma subunit (S. cerevisiae) 
vesicle transport throuqh interaction with t-SNAREs lb homoloq 
RIKEN cDNA 4922501H04 qene 
thymosin beta 4 
ribosomal protein, larqe, PI 
ribosomal protein L31 
Mus musculus qene for ribosomal protein L27A. complete cds. 
RIKEN cDNA 2310022M17 qene 
ribosomal protein S8 
small nuclear ribonudeoprotein polypeptide G 
RIKEN cDNA 1010001M12 qene 
Mus musculus, quanine nucleotide bindlnq protein (G protein), qamma 5, clone MGC: 
ferritin heavy chain 
Mus musculus, ribosomal protein L23a, clone IMAGE:4988735, mRNA, partial cds 
Purklnle cell protein 4 
ribosomal protein Sll 
S100 calcium bindlnq protein Al 
GTP cyclohvdrolase 1 
RIKEN CDNA 2410089B13 qene 
Mus musculus ferritin L-subunit qene exons 1-4, complete cds. 
ESTs 
RIKEN CDNA 2310040A07 qene 
RIKEN CDNA 1110060M21 qene 
qamma-amtnobutvric acid receptor associated protein 
RIKEN CDNA 2810004N20 qene 
monocyte to macrophaqe differentiation-associated 
deformed epidermal autorequlatory factor 1 (Drosophila) 
DNA seqment. Chr 2. ERATO Dol 217, expressed 
Cluster Incl AF100956:Mus musculus major histocompatibility locus class II reqion 
RIKEN CDNA C330016H24 qene 
ribosomal protein S17 
RIKEN cDNA 4933439F18 qene 
RIKEN CDNA 1810037117 qene 
ESTs 
Mus musculus, Similar to hypothetical protein FU21079, 
67kD, ribosomal protein 
Mouse ribosomal protein L30 qene, complete cds. 
RIKEN cDNA 2900074C18 qene 
RIKEN CDNA 3110038K10 qene 
cadherln 11, alternatively spliced 
Mus musculus, clone IMAGE:4504748, mRNA 
RIKEN cDNA 0610010E21 qene 
acidic ribosomal phosphoprotein PO 
RIKEN cDNA 2410088K19 qene 
RIKEN cDNA 2210013021 qene 
ribosomal protein L13 
mitochondrial ribosomal protein L52 
ESTs 
ribosomal protein S2 
expressed sequence AI463719 
RIKEN cDNA C530005M16 qene 
protein kinase Inhibitor, qamma 
NADH dehvdrooenase (ubiquinone) 1 alpha subcomplex 2 
ESTs, Hlqhlv similar to NUMM MOUSE NADH-ublqulnone oxldoreductase 13 kDa-A 
RIKEN cDNA 2010003014 qene 
MORE ABUNDANT IN THE POLYSOME FRACTION THAN IN THE TOTAL 
protein kinase C, lambda 
RIKEN cDNA 1110007C02 qene 
NADH dehydrogenase flavoprotein 1 
ESTs 
actin, beta, cytoplasmic 
RIKEN cDNA 2210013K02 qene 
qlvceraldehvde-3-phosphate dehvdrooenase 
expressed sequence AW048948 
RIKEN cDNA 2410015A15 qene 
expressed sequence AI481191 
T/P 
6.12 
5.35 
4.58 
4.46 
4.45 
4.39 
4.31 
4.27 
4.13 
4.07 
4.04 
3.96 
3.94 
3.78 
3.62 
3.62 
3.54 
3.34 
3.29 
3.27 
3.15 
3.13 
3.12 
3.07 
3.04 
3.04 
3.04 
3.02 
2.99 
2.97 
2.87 
2.86 
2.83 
2.82 
2.82 
2.81 
2.75 
2.71 
2.69 
2.69 
2.66 
2.62 
2.61 
2.61 
2.57 
2.55 
2.50 
2.50 
2.49 
2.48 
2.47 
2.46 
2.45 
2.42 
2.40 
2.39 
2.39 
2.37 
2.36 
2.35 
2.30 
2.29 
2.28 
2.28 
2.27 
2.26 
2.25 
2.24 
2.23 
2.19 
2.18 
2.18 
2.18 
2.16 
2.16 
2.12 
2.10 
2.10 
2.09 
2.07 
2.02 
2.00 
0.70 
0.69 
0.66 
0.61 
0.60 
0.59 
0.54 
0.54 
0.51 
0.38 
Fig. 14: Comparison between the polysome fractions of W T and Nova-1-null 
animals: For each gene, two sets of intensity values were compared: WT polysome and 
KO polysome. Each set contained three values, corresponding to the number of 
replicates. The intensity values in the polysome data sets were normalized to the 
corresponding values in the total data sets. The graph, with the same conventions as in 
figure 14, represents exclusively the genes that shown significant difference (/-test, 
p<0.05). 
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Replicates: KO Polysomes W T Polysomes KO Total W T total 
Table II: 
List of Genes whose intensity is at least two times higher in the Wild Type polysome 
fraction normalized to Total than in the Nova-null polysome fraction (p<0.05). 
Entries corresponding to genes with a described function related to post-synaptic 
densities, ras/rho signaling pathways and dynamic organization of the cytoskeleton in 
neurites are colored in light blue. Transcription factors are labeled in purple. 
Metalloproteases are labeled in yellow. 
Table III: 
List of Genes whose intensity is at least two times higher in the Nova-1-null mutants 
polysome fraction normalized to Total than in the Wild Type polysome fraction (p<0.05). 
Color convention are the same as in Table II. 
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T A B L E II: Decreased in the Polysome Fraction of K O 
Name 
ESTs(unknown) 
EST(unknown) transcription factor? 
Mouse CNK (connector enhancer of ksr) 
RICKEN cDNA 
Damage-induced neuronal endopeptidase (DINE) 
RICKEN cDNA 
cell division cycle 45 homolog -like 
Rho GTPase activating protein 6 
ESTs 
RICKEN cDNA 
ESTs 
insulin like peptide? 
endothelin converting enzyme 2 
RICKEN cDNA 
RICKEN cDNA 
ESTs 
Ngfi-A binding protein 1(NAB1) 
helicase-like transcription factor 
ADAMTS15 
ras homolog gene family, member J 
ESTs 
ESTs 
melastatin 1 
ESTs 
Fas-activated serine/threonine kinase 
acid phosphatase 2, lysosomal 
RICKEN cDNA 
RICKEN cDNA 
RICKEN cDNA 
ESTs 
RICKEN CDNA 
nPAS 1 
RICKEN cDNA 
SPLASH (PLA2IID),phospholipase A2 
ESTs(unknown) 
RICKEN cDNA 
similar to cleavage stimulation factor subunit 3 
structural protein of Rauscher oncovirus(plO) 
DAP-1 
(WT P/WT TV(KO P/KO T) 
6.13 
5.29 
4.79 
4.3 
4.16 
4.01 
3.92 
3.53 
3.42 
3.38 
3.35 
3.19 
3.12 
3.07 
2.95 
2.63 
2.63 
2.56 
2.55 
2.5 
2.49 
2.44 
2.43 
2.43 
2.41 
2.4 
2.36 
2.32 
2.3 
2.28 
2.26 
2.19 
2.19 
2.19 
2.19 
2.18 
2.15 
2.05 
2.04 
p-value 
0.00159 
0.00332 
0.04817 
0.02798 
0.03258 
0.04257 
0.00594 
0.01020 
0.04506 
0.01594 
0.04348 
0.03302 
0.02224 
0.02317 
0.03850 
0.04425 
0.01900 
0.00563 
0.04784 
0.02647 
0.01853 
0.02088 
0.04842 
0.01588 
0.04615 
0.03946 
0.03320 
0.04149 
0.00626 
0.00620 
0.01563 
0.04362 
0.00720 
0.02959 
0.02530 
0.02309 
0.02142 
0.00987 
0.02370 
T A B L E III: Increased in the P o l y s o m e Fraction of K O 
GENBANK Name 
AV085172 selenium binding protein 2 
AV330090 (PNKP) polynucleotide kinase 3'- phosphatase 
AI465103 VACM(vasopressir) activated Calcium mobilizing) 
AV092700 epithelial membrane protein 3 
AV294462 unknown 
AV250850 RIKEN cDNA 
AA623482 Similar to PDZ protein Interacting with TC10 
X00686 Mouse gene for 18S rRNA. 
AV378373 Filamin 
AW049330 EST unknown 
AW123239 EST unknown 
AA919877 Putative membrane protein 
U72059 chloride channel regulator Icln(pseudogene) 
AV094422 EST unknown 
AW122825 EST unknown 
AI854147 brain and acute leukemia (BALC) cytoplasmic 
AW045678 RIKEN cDNA 
AW045965 RIKEN cDNA 
U62674 Cluster Ind 
AI837599 neural stem cell derived neuronal survival protein 
AI848299 RIKEN cDNA 
AW048995 clone IMAGE 
AW120523 EST unknown 
AA839260 EST unknown 
AI850861 EST unknown 
AI152936 RIKEN cDNA 
A1585778 EST unknown 
AI850923 EST unknown 
TV(WTP/WTT) 
9.92 
5.87 
4.73 
4.51 
3.91 
3.89 
3.44 
3.19 
3.12 
2.95 
2.92 
2.76 
2.64 
2.43 
2.42 
2.4 
2.4 
2.36 
2.35 
2.3 
2.29 
2.27 
2.14 
2.09 
2.08 
2.07 
2.07 
2.02 
p-value 
0.00102 
0.03178 
0.03356 
0.03013 
0.02058 
0.04504 
0.00351 
0.03115 
0.03880 
0.00885 
0.00041 
0.04070 
0.00409 
0.03592 
0.03813 
0.00534 
0.04961 
0.00679 
0.04245 
0.03956 
0.03593 
0.02920 
0.00425 
0.00918 
0.02885 
0.04229 
0.00915 
0.00999 
C h a p t e r 5 : 
Role of phosphorylation in control of splicing and translation in the neural system: 
Phosphorylation is arguably the most frequent reversible post-translational 
modification in the nervous system. Innumerable examples of reversible change of the 
proprieties of a protein due to addition of a phosphate group to the hydroxyl groups of 
Serine, Threonine or Tyrosine have been described. In neurons, like in all cell types, 
phosphorylation of proteins is massively employed in signal transduction pathways that 
convey information from the extra-cellular environment to the inside of the cell. Despite 
the enormous complexity of the characterized signal transduction pathways identified in 
the nervous system, one can find a few themes common to the vast majority of them 
(reviewed in Siegelbaum et al., 2000). In the most schematic form, all signal transduction 
pathways in the CNS are initiated by an external signal or first messenger, which binds a 
receptor. Protein phosphorylation plays a major role in the modulation of the synaptic 
functions in response to the stimulation metabotropic receptors. The complex of ligands 
and receptor activates downstream events through the activation of another set of 
molecules. Despite the great variety of molecules involved in this step, pathways of 
signal transduction acting through phosphorylation can be grouped in two large groups: 
those initiated by tyrosine kinase receptors and those initiated by G protein-coupled 
receptors. The receptor tyrosine kinases bind peptide ligands, mostly cytokine and growth 
factors. The activation of tyrosine kinase pathways results mostly in long term changes in 
neuronal function through changes in gene expression. G protein-coupled receptors 
constitute a large family of integral proteins characterized by the presence of seven 
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transmembrane domains and by the functional coupling with guanine nucleotide-binding 
proteins (G proteins). G proteins, in turn, activate or inhibit enzymes often referred to as 
primary effectors, which produce second messengers. Second messengers transducing 
signals from G protein-coupled receptors in neurons are essentially cyclic AMP, which 
activates Protein kinase A, Inositol triphosphate, Diacyl Glycerol and Ca2+, which 
activate protein kinase C, and, through the activation of phospholipase A2, Arachidonic 
Acid and its metabolites. The second messengers, in turn, trigger biochemical cascades, 
often involving the phosphorylation of numerous other substrates, the activation of other 
signaling cascades, or the mobilization of Ca2+ions from intracellular stores. The 
physiologic outcome of the activation of a signal transduction pathway is often the result 
of the interaction with many other pathways that can converge or antagonize each other. 
LTP, for example, has been shown to be affected by the protein kinase A, calcium 
calmodulin kinase IV and MAP kinase cascades, all which converge in the 
phosphorylation of CREB (reviewed in Barco et al, 2003). 
Phosphorylation is known to play important roles in the regulation of pre-mRNA 
splicing and regulation of mRNA translation. I already mentioned the role of mTOR in 
synaptic plasticity (Tang et al., 2002), and the role of phosphorylation of eEF2 in the 
increase of ccCaMK II synthesis in response to stimulation of the NMDA receptor 
(Scheetz et al., 2000). Changes in alternative splicing have been observed in numerous 
instances in intact animals in response to behavioral pattern and physiological stimulation 
as diverse as stress, nutritional status, cocaine and ethanol abuse (reviewed in Stamm, 
2002). In few cases, however, has the activation of a specific signaling pathway directly 
been shown to be involved in the regulation of alternative splicing choices. Notably for 
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the neural functions, a pyrimidine-rich element has been identified, that is necessary and 
sufficient to confer regulation by Ca27Calmodulin-dependent protein kinase IV (CaMK 
IV). The element is found in the STREX exon of the BK potassium transcript, and the 
activation of CaMK IV inhibits its inclusion, thereby likely decreasing the Ca2+ 
sensitivity and opening probability of the channel (Xie and Black, 2001). 
Nova 1 is a phosphoprotein: 
The alternative splicing of the seventy-two nucleotides long exon H is known to 
generate two isoforms of Nova-1 (Buckanovich et al., 1993). Exon H encodes a domain, 
that we will call domain H, characterized by its high content of serine and threonine 
residues (twelve), five of which are preceded or followed by prolines, suggesting that 
they may be phosphorylation sites (Fig. 15B) (Kemp and Pearson, 1990). Furthermore, 
Nova-1 recognition motifs have been described in the intron downstream of exon H, and 
in the exon H itself, suggesting that the alternative splicing of exon H may be regulated 
by Nova itself (Buckanovich and Darnell, 1997). These features suggest that exon H may 
encode a regulatory domain, whose inclusion is object of further regulation. To verify the 
first part of this hypothesis we tested whether Nova-1 is phosphorylated in vivo and 
whether differences in the level of phosphorylation exist between the two isoforms. 
Vectors encoding the two isoforms were transfected into neuroblastoma N2a cells, 
radioactive inorganic phosphate was added to the medium, and the protein purified by 
immunoprecipitation was analyzed by autoradiography for the incorporation of 
phosphate. The isoform containing domain H is robustly phosphorylated, more than ten 
times above the level of the form without the domain (Fig. 15 A and 15D). Analysis of the 
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sequence of the domain H shows that six residues match the consensus sequence for 
phosphorylation sites by two protein kinases, protein kinase C (PKC) and Glycogen 
Synthase Kinase 3 (GSK 3) (Fig. 15B). We substituted alanine residues for some of the 
serine and threonine residues in various combinations by site-directed mutagenesis to try 
to identify the phosphorylation sites. The phosphorylation level was unchanged when the 
sites 5 and 6 were mutated, and was reduced to the level of the form not containing 
domain H when sites 2 and 4 or 2, 5 and 6 were mutated, suggesting that site 2 is 
necessary for phosphorylation (Fig. 15C). The mutation of site 2 alone to alanine was 
sufficient to reduce the intensity of phosphorylation to the level of the form not 
containing domain H (Fig. 15D). These data suggest that the second serine of domain H 
is the only site of phosphorylation. 
We have not been able to observe functional differences between the two 
isoforms of Nova-1, nor between the forms generated by site-directed mutagenesis and 
the wild type. Both the isoforms generated by alternative splicing are engaged in the 
same set of known protein-protein interactions (Fig. 7B), and they have a similar effect in 
promoting the inclusion of exon 3a of the Glycine receptor minigene (Fig. 16A). 
Furthermore, the mutation of the second Serine to Glutamate, which mimic a phosphate 
group because of its negative charge, has the same effect on splicing of the Glycine 
receptor minigene as the mutation to Alanine, which cannot be phosphorylated (Fig. 
16B). Furthermore, the intracellular distribution of the two isoforms differing for the 
inclusion of the domain H does not show any major difference (Fig. 16C). 
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Discussion: 
We established that Nova 1 is a phosphoprotein, and that the phosphorylation site 
is in an alternatively spliced exon. A weakly labelled band corresponding to the isoform 
not containing the alternative exon is observed in some of the experiments, indicating that 
much less utilized phosphorylation sites exist in the protein outside domain H. It is 
possible that the second serine of exon H is not the only phosphorylated site, but a site 
whose phosphorylation is required for the phosphorylation of a second site, a mode of 
phosphorylation that has been shown for Glycogen Synthetase Kinase 3 (GSK3) 
substrates, for example (reviewed in (Biondi and Nebreda, 2003). We have not been able 
to detect a functional difference in the ability to regulate splicing nor in the intracellular 
localization of the isoforms differing for the alternative inclusion of exon H, nor between 
the mutants. We do not know at present what the functional role the phosphorylation of 
Nova-1 is. The H domain primary sequence, which is rich in purine, serine, threonine, 
matches the consensus for PEST regions as evaluated by a web-based algorithm, 
PESTFind (http://www.icnet.uk/LRITu/projects/pest/). It is well established that PEST 
motifs serve as proteolytic signals to target the proteins for degradation by the 26S 
proteasome, in a process that involves phosphorylation-dependent ubiquitination 
(Rechsteiner and Rogers, 1996). Although we have not directly measured the half-life of 
the two isoforms in a pulse-chase experiment, we have no indication that the isoform 
containing exon H is less stable than the one not containing it. PEST sequences have also 
been demonstrated not to affect protein stability in a few instances (Chen and Clarke, 
2002). Bicoid (Bed), a homeodomain transcription factor, is also a translational regulator 
of caudal in Drosophila. The binding of a Bed-binding region (BBR) in the 3'UTR of 
102 
caudal through the homeodomain is not sufficient to achieve such regulation: a PEST 
region in Bicoid is required for the translational repression of caudal (Niessing et al., 
1999). Furthermore, deletion of a region that includes a PEST domain in CPEB abrogates 
tubulin binding in vitro and centrosome localization in vivo, suggesting that PEST 
domain may mediate the interaction of CPEB with the cytoskeleton (Groisman et al., 
2000). Analogously, one can envision a scenario in which the H domain exerts an 
inhibitory effect on translation of the mRNA bound to Nova, and phosphorylation could 
exert some regulatory effect, for example releasing the inhibition in response to the 
activation of a signaling pathway. The interaction to the cytoskeleton, as in the CPEB 
example, is also an interesting hypothetical scenario for the function of the H domain, 
since RNA granules reactive to anti-Nova antibodies have been described in dendrites, 
presumably carrying mRNA to intracellular destinations (Darnell and Triller, 
unpublished). 
103 
Figure 15: Nova-1 is phosphorylated in a domain encoded by cassette exon H: 
(A) Comparison between the level of phosphorylation of Nova-1 H+ and Nova-1 H- in 
N2a cells. Cells were transfected with constructs encoding the two isoforms tagged with 
T7, and inorganic 32P was added to the medium. After 5 hrs incubation, cells were 
harvested, lysated and and immunoprecipitated. The pellet was treated with RNase A for 
15 minutes at room temperature between the second and third washing steps. The 
precipitated material was resolved on a SDS PAGE, transferred to a nylon membrane and 
exposed to a radiography film (upper panel). Subsequently, the membrane was probed 
with anti body against T7 tag (lower panel). 
(B) Sequence of the domain encoded by exon H (H domain). The residues colored in red 
and numbered 1 to 6 are the phosphorylation sites predicted by Prosite 
(http://us.expasy.org/prosite/) and Scansite (http://scansite.mit.edu/). 
(C) Identification of the phosphorylation site by site-directed mutagenesis. Metabolic 
phosphorylation assay was performed as in (A). Expression constructs encoding Nova-1 
H+ (lane 1), Nova-1 H- (lane 2), and point mutants in which the indicated residues were 
mutated to Alanine (lanes 3 to 6) were transfected. The numbers above the lanes refer to 
the numeration of the phosphorylation sites in Fig. 16B. 
(D) Constructs encoding Nova-1 H+ (lane 1), Nova-1 H- (lane 2) and a Nova-1 H+ in 
which the Serine of site 2 was mutated to Alanine were utilized for the 
transfection/metabolic labeling assay as in (A). 
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Figure 16: The state of phosphorylation of site 2 does not affect the properties of 
Nova-1 in splicing and localization: 
(A) Co-transfection splicing assay of GlyRcx2 minigene in 293 T cells. Increasing amount 
of DNA constructs encoding Nova-1 H+ and Nova-1 H- were co-transfected with a fixed 
amount of vector encoding GlyRa2 minigene. The ratio of the spliced isoforms was 
assessed by RT PCR like in figure 2. 
(B) The same co-transfection assay was employed by co-transfecting increasing amount 
of vector encoding Nova-1 carrying a mutation of the site 2 either to Alanine or to 
Glutamate with GlyRa2 minigene. 
(C) Intracellular localization of the two Nova-1 H+ and H- isoforms was assessed by 
immunocytochemistry in transfected N2a cells. 
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C h a p t e r 6: D i s c u s s i o n 
W e demonstrated that Nova-1 regulates alternative splicing in several experimental 
systems. The analysis of Nova-1-null mutant animals had shown that the splicing of a 
candidate target RNA for Nova-1, GlyRa.2 pre-mRNA, was mis-regulated specifically in 
the areas of the CNS where Nova-1 is normally expressed. The alternative exon 3A, 
which is preceded by an intronic sequence matching the consensus for Nova binding, is 
under-utilized in the Nova-null animals. Consistent with this, a reciprocal increased 
utilization of exon 3A was observed upon co-transfection of Nova with a GlyRa2 
minigene in three different cell lines. The mutation of the candidate Nova-binding 
intronic sequence abolished the Nova-dependent effect. Furthermore, we demonstrated 
by UV cross-linking and in vitro splicing assay that the effect of Nova on alternative 
splicing is at the RNA level. Nova protein from brain extracts specifically cross-links the 
sequence (UCAUY)3 but not the mutant sequence (UAAUY)3. Purified Nova-1 fusion 
protein added to HeLa nuclear extract promotes the splicing of a cassette exon of an 
artificial pre-mRNA derived from GABAARy2 pre-mRNA, another gene whose splicing 
was found to be mis-regulated in the Nova-null mutants. 
Nova-1 was the first described tissue-specific regulator of alternative splicing in 
vertebrates (Jensen et al., 2000a). Few other such factors have been described since then. 
A largely brain-restricted protein similar to PTB called brain PTB (brPTB) or neural PTB 
(nPTB), was discovered in a search for proteins interacting with Nova and independently 
106 
biochemically purified (Markovtsov et al., 2000; Polydorides et al., 2000). A family of 
six RNA binding proteins called CELF (CUBP and Etr-1-like factors) or Brunol (Bruno-
like) have been recently described, some of whose members are exclusively expressed in 
one or two tissues (Ladd et al, 2001; Suzuki et al., 2002). ET3, a member of this family, 
increases the splicing of exon 5 of chicken cardiac Troponin by interacting with intronic 
elements called muscle-specific enhancers (MSE) (Charlet et al., 2002; Ladd et al., 
2001). Another member of this family, NAPOR1, is enriched in restricted areas of the 
central neural system, and the pattern of splicing of /V-methyl-D-aspartate (NMDA) 
receptor pre-mRNA correlates with its distribution. Experiments in transfected cells show 
a NAPOR1-dependent effect on a NMDA minigene splicing, and identifies particular 
intronic elements required for such regulation (Zhang et al., 2002). The RNA-binding 
protein Fox-1, whose expression is restricted to brain, heart and skeletal muscle in 
vertebrate, has recently been shown to regulate the alternative splicing of several genes 
containing its binding sequence UGCAUG (Jin et al, 2003). A few other tissue-restricted 
splicing regulators have been identified in invertebrates, for instance the neural-specific 
ELAV as well as the ovarian-specific Half Pint in Drosophila (Koushika et al., 1996; 
Koushika et al., 2000; Lisbin et al., 2001; Van Buskirk and Schupbach, 2002). 
The first well-characterized cascade of regulated alternative splicing, the sex 
determination pathway in Drosophila, consists of a series of binary choices between a 
regulated and a default pathway. Female-specific factors (Sex-lethal, Transformer) 
instruct the regulated, female-specific pattern of splicing; in absence of such factors, the 
pre-mRNAs are processed along the male-specific pathway, apparently the default 
pattern (reviewed by Wang et al., 1997). The observation that the tissue-specific exons in 
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vertebrate are most often poor splice substrates because of their small size and poor 
match to the consensus splice sequences prompted the idea that for vertebrates the exon 
skipping in the inappropriate cell types is also a default pathway (Black, 1991; Dominski 
and Kole, 1991; Dominski and Kole, 1992; Xu et al., 1993). The discovery of the 
antagonistic effects of ASF/SF2 and hnRNPAl on the 5' splice site choice (Mayeda and 
Krainer, 1992) revealed a general feature of alternative splicing regulation in vertebrates: 
the choice between alternative pathways of splicing is the result of the interplay of 
activating and inhibiting factors. Most of the studied cell-type specific events have 
revealed complex mechanisms in which activating factors not only promote splicing, but 
also counteract inhibitory mechanisms. For example, in the case of the exon Nl of c-src 
splicing, one of the best-characterized instances of tissue-specific alternative splicing, 
several activators have been identified. KSRP, hnRNP H and hnRNP F promote the 
inclusion of exon Nl by binding the Downstream Control Sequence (DCS), while 
ASF/SF2 exerts its activating role interacting with the exon itself. These activators are 
required not only to overcome the intrinsic weakness of exon Nl, but also to counteract 
the inhibitory role of PTB, which binds on both sides of the alternative exon, possibly 
forming a RNA looping complex that masks exon Nl to the splicing machinery 
(reviewed in Black, 2003). brPTB (or nPTB) is a weaker inhibitor of the inclusion of 
exon Nl in vitro than PTB thus providing a possible mechanism for the tissue specificity 
of exon Nl inclusion (Markovtsov et al, 2000). Analogously, the inclusion of exon 5 of 
cardiac Troponin (cTNT) is controlled by a balance of the positive action of ETR-3 -a 
member of the CELF family- and the inhibitory action of PTB. The proportion of exon 
inclusion doubles when fibroblasts are transfected with a dominant negative form of 
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PTB, and returns to baseline when a dominant negative form of CELF is co-transfected 
(Charlet et al., 2002). The data on Nova-1 co-transfection with brPTB suggest a similar 
scenario, at least in the case of regulation of alternative splicing of GlyRa2, where brPTB 
antagonizes the effect of Nova (Polydorides et al., 2000). While we have not yet tested 
the effect of co-transfection of PTB or brPTB on the Nova-dependent activation of 
GABAARy2 splicing, previous studies have demonstrated an inhibitory effect of PTB on 
the splicing of this substrate (Ashiya and Grabowski, 1997). The interactions of Nova-1 
with U2AF65 and Ul 70K suggest that Nova can also regulate alternative splicing 
through a direct effect on recruitment of the spliceosome (Fig. 17A). In the case of the 
regulation of GABA yr2 pre-mRNA splicing by Nova, one can hypothesize that the 
interaction with Ul 70K is instrumental to recruit the entire Ul snRNP to the 5' splice site 
most proximal to the intronic Nova binding site. TIA1, a splicing activator acting through 
an intronic enhancer, has been shown by psoralen-mediated UV cross-linking assays to 
increase the recruitment of Ul snRNP to a weak 5'splice site through its interaction with 
Ul-C (Forch et al., 2000; Forch et al., 2002). Future in vitro studies will employ a similar 
approach to verify a similar effect on Ul recruitment by Nova through Ul 70K. 
Some features of the Nova-1-null mutants, like tremors and motor dysfunctions 
are consistent with functional failure of inhibitory responses in the CNS, as one would 
expect from impairment of the Glycinergic and GABAergic pathways. Several 
observations show that the GABAARy2 subunit is a very important component of the 
GABAA receptor. Mutations of the GABAARy2 subunit have been documented in 
association with various forms of familial epilepsy (Baulac et al., 2001; Bianchi et al., 
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2002; Bowser et al, 2002; Harkin et al, 2002; Marini et al., 2003; Wallace et al., 2001). 
The targeted disruption of the entire GABAARy2 subunit in mice results in animals that 
are normal at birth, but subsequently show retarded growth, sensor-motor dysfunctions 
and reduced life span. Consistent with previous studies identifying GABAARy2 subunit as 
the target of benzodiazepines, the mutant mice are insensitive to this family of drugs 
(Gunther et al., 1995). However, present knowledge concerning the differences in 
physiologic proprieties of GABAARy2L and S isoforms does not provide a satisfactory 
explanation for the dramatic phenotype of Nova-1-null mutant mice. The alternative exon 
9 of GABAARy2 encodes a stretch of eight amino acids that are thought to contribute to 
the intracellular loop between the third and the fourth putative transmembrane domains of 
GABAARy2 (Pritchett et al., 1989). Mice resulting from the specific deletion of the 
alternative exon 9 show only slightly altered responses in tests designed to measure the 
level of anxiety, and higher sensitivity to benzodiazepines compared to their wild type 
littermates (Homanics et al., 1999; Quinlan et al., 2000). Even less is known about the 
features of the two isoforms of GlyRa2 generated by the inclusion of exon 3 A or 3B: the 
two exons encode twenty-three aminoacid long extracellular domains that differ by only 
two amino acids (Kuhse et al., 1991), and no functional differences have been described. 
It is probable that the phenotype of Nova-1-null mice results from defects of the 
regulation of other genes at the level of splicing beside GlyRa2 and GABAARy2, and 
possibly, given the high degree of integration of the mechanism of gene expression, at the 
level of export, localization of the messages and translation. Cytoplasmic and dendritic 
distribution of Nova has indeed been demonstrated by immunocytochemistry both in 
cultures of primary neurons and in ventral horn spinal cord neurons (Triller and Darnell, 
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unpublished). To gain some insight in the function of the cytoplasmic Nova, we began 
the characterization of the cytoplasmic structures Nova interacts with, by analyzing 
cytoplasmic extracts in linear density gradients. Rather large cytoplasmic structures, 
sedimenting around 80S, are observed in extracts of animals from P3 to P30. Unlike 
translating polysomes, these structures are resistant to treatment with high concentration 
of EDTA. We are inclined to consider these structures mRNPs, similar to structures of 
similar size characterized as reactive to antibodies against FMRP, Hu and ctCP (Antic 
and Keene, 1998; Feng et al., 1997; Ji et al., 2003). Further experiments are required to 
unambiguously establish the nature of these structures. Poly(A) specific fractionation by 
Chromatography on OHgo(dT)-cellulose (Dreyfuss et al., 1984a; Dreyfuss et al., 1984b) 
and a more stringent treatment with RNAse will verify their RNA content. An amount of 
Nova that increases with age, up to around twenty-five percent at P30, sediments in the 
denser fractions of the gradient, and shifts to the upper part of the gradient in presence of 
EDTA, a behavior consistent with association with polysomes. 
In an attempt to achieve a broader picture of the changes in gene expression levels 
underlying the phenotype of the Nova-null mutants, we utilized the RNA purified from 
the polysomal fractions of the gradient to interrogate DNA microarray. We compared the 
information obtained with the levels of gene expression in the input material. The overall 
number of sequences that show variations between wild type and mutants is rather small 
compared to the variations observed comparing polysome fractions from lymphoblastoid 
cell lines expressing normal or non-functional FMRP (Brown et al., 2001). As in Brown 
et al., 2001, we observed both increased and decreased abundance of specific messages in 
the polysomal fraction. Little information is available about the biological proprieties of a 
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quite large portion of the sequences that show modified levels in polysomes in Nova-null 
mice. At least six sequences have known biological proprieties that can be related to a 
role in growth cone functions, post-synaptic architecture and related signaling pathways. 
Two of them are increased and four decreased in absence of Nova, exclusively in the 
polysome fraction. We also found three metalloproteases to be decreased in the 
polysome-associated pool of mRNAs in absence of Nova. Metalloproteases have a 
demonstrated role in neurites growth during development of the CNS, among many other 
functions (reviewed in (McFarlane, 2003; Yong et al., 2001). 
While the decreased levels of these messages in the polysomes purified from 
Nova-1-null mice is consistent with a positive role of Nova-1 in the regulation of their 
translation, many issues remain open for future investigation. The data obtained from the 
microarrays only provide a picture of the final outcome of potentially many events 
consequent to the absence of Nova-1. Although the decreased level of messages 
exclusively in the polysomes hint at a role of Nova in translational regulation, the 
modality of such action is unclear. One first point to be addressed is the validation of 
consistent changes in the level of the proteins encoded by the messages whose abundance 
is altered. Another important question is whether the altered level of messages are due to 
a direct effect of Nova through interaction with the proposed target RNAs. Although sets 
of potential Nova binding sites are identifiable by inspection of the sequences, no 
evidence of a physical interaction is presently available. 
Most of the described mechanisms of translational regulation by RNA binding 
proteins in eukaryotes involve an inhibitory effect that is removed upon the delivery of an 
appropriate signal. Among the best studied examples, hnRNP K, El and E2 are known to 
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inhibit the initiation of translation of 15 L O X m R N A by binding the 3'UTR (Ostareck et 
al., 2001; Ostareck et al., 1997). Iron regulatory proteins (IRP) regulate translation of 
ferritin by inhibiting initiation through an interaction with the 5' UTR of the message; 
upon increase of the Iron levels which are bound by IRP, a conformational change of the 
proteins induces the release of the inhibition (reviewed in (Hentze and Kuhn, 1996). 
Nova could conceivably inhibit translation with analogous mechanisms at the level of 
initiation. On the contrary, the decreased levels of mRNAs in the Nova-null polysomes 
suggest a positive effect of Nova on their translation. While mechanisms of general 
activation of cap dependent translation through mTOR protein kinase are well 
characterized, few examples of translational activation of subset of messages by 
sequence-specific RNA binding proteins are known. In Drosophila, Aubergine has been 
shown to enhance oskar translation in the ovary (Wilson et al., 1996). Motifs with 
translational enhancer activity have been identified in plants (Yamamoto et al., 1995). 
The RNA-trafficking sequence (RTS) originally identified as a determinant for transport 
of Myelin Basic Protein (MBP) mRNA is a vertebrate translational enhancer. hnRNP A2 
acts on RTS as a trans-activator (Kwon et al., 1999). The finding of simultaneous 
increase of some messages and decrease of others in the polysome fraction in response to 
the abolition of Nova is seemingly paradoxical. Nonetheless, translational control factors 
seem to act in a combinatorial fashion in many instances. Analogous to well-documented 
principles of transcriptional regulation, distinct protein-protein interactions between RNA 
binding proteins are thought to discriminate among various RNA substrates and yield 
specific biological outcomes (reviewed by Wickens, M., et al., 2000). HnRNP El acts 
with hnRNP K to repress 15 LOX translation, by binding the DICE element (Ostareck et 
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al., 1997), but it has additional roles as well. In fact, H n R N P El with hnRNP E2 is also 
part of the a-complex that promote the stability of a-globin mRNA by binding to CU-
rich sequences in the 3'UTR, ultimately promoting the expression of this gene (Kiledjian 
et al., 1995; Wang et al., 1995). Therefore, by interacting with two different mRNAs as 
part of two different protein complexes, hnRNP El exerts two opposite effects on the 
expression of two different genes in the same cell type. Furthermore, the mRNAs 
analyzed on microarrays were purified from spinal cord, which is constituted by a 
heterogeneous population of neuronal subtypes: inhibitory and activating actions of Nova 
on translation could conceivably not take place simultaneously in the same cell. Given 
the similar sedimentation pattern on linear density gradient, and the demonstrated 
physical interaction, Hu proteins are possible functional partners of Nova in the 
formation of complexes with a positive role on translation. Increased translation of 
neurofilament M mRNA has been described in response to over-expression of HuB, in 
absence of stabilization of the message (Antic et al., 1999). The translation of a number 
of other messages has been shown to be increased in response to Hu proteins, but the 
mechanism of such effect is not known (Keene, 2001). 
A noticeable feature of the mechanisms of translational control in early 
Drosophila and C.elegans development is the strict coordination of mRNA localization 
and translation (Johnstone and Lasko, 2001). In several instances, the translation of 
particular mRNAs in an inappropriate location in the cell could have damaging 
consequences; therefore mRNA is complexed with proteins that keep it masked from the 
translational apparatus during transport and mediate interactions with cytoskeleton and 
motor proteins. One possible interpretation of the observed decrease of certain RNA in 
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the polysomes of Nova-1-null animals is the loss of a hypothetical localizing effect. One 
could envisage a scenario where in absence of Nova its mRNA targets do not reach a 
location in the cell where they are usually translated. If, in order to be translated, these 
mRNAs are required to be localized in the dendrites or in the growth cone, and the 
absence of Nova impaired such spatial targeting, one would expect a diminished 
engagement in the polysomes in the Nova-null mice. An obvious implication of this 
model is that the mRNAs that we found decreased in the polysomes should be normally 
localized in discrete domains of the cytoplasm. 
The observation of splicing defects and translational alterations in the Nova-null 
mutants makes it tempting to consider a direct connection between the nuclear and 
cytoplasmic events regulated by Nova-1. However, we have not observed alterations of 
the polysome distribution of GABAR and GlyR mRNA in absence of Nova. The 
knowledge of translational alteration in Nova-null mutants puts us in the position to 
tackle the hypothesis of coupling between the nuclear and cytoplasmic events regulated 
by Nova from the cytoplasmic end of the mRNA's journey. If that is the case, one would 
expect changes in the pattern of alternative splicing of those mRNAs whose level is 
altered in the polysomes. Recent investigations conducted in our laboratory have led to 
the isolation of a number of RNAs based on their physical association with Nova. The 
splicing of some of these new targets is modified in absence of Nova (Ule and Jensen, 
unpublished). Interestingly, a number of them encode proteins involved in clustering of 
receptors, post-synaptic structures and growth cones, similar to the mRNAs we have 
found altered in the polysomes. However, no overlapping RNAs between the two 
screenings have emerged at present. The data emerging from diverse approaches are 
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beginning to draw a rather complex picture of the functional role of Nova in the 
regulation of gene expression. We have shown that Nova affects the pattern of alternative 
splicing of an as yet unknown number of genes, and we provide initial observations 
suggesting a role in the regulation of cytoplasmic events of gene expression (Fig. 17b). 
Functionally related genes encoding receptors, components of the post-synaptic densities, 
growth cones and elements of related signal transduction pathways are regulated by Nova 
at different steps of their expression pathway. 
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Figure 17: Functions of Nova in R N A metabolism: 
(A) Nova acts in the nucleus as a regulator of alternative splicing. Our data suggest that 
Nova binds to intronic enhancers and promotes the utilization of the most proximal splice 
sites of the intron it is bound to. This observations and the interactions with Ul 70K and 
U2AF65 suggest that Nova recruits components of the basic splicing machinery to the 
closest splice sites. 
(B) Changes in the relative abundance of messengers specifically in the polysome 
fraction in absence of Nova-1 suggest that the pehnotype of Nova-1-null mice is at least 
partially imputable to alterations of gene expression at the level of translation. Since 
Nova has been observed in discrete foci in the dendrites, coincident with reactivity for 
component of the ribosome, one can speculate a functional role in regulation of peculiar 
aspect of translation in neurons, like coupling of translation to neural activity in 
phenomena of synaptic plasticity. Consistently with this hypothesis, several messengers 
whose association with polysomes is altered in absence of Nova-1 encode proteins with 
functions related to the maturation or function of synaptic contacts. 
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